

THE 41ST MEETING OF THE EUROPEAN PANCREATIC CLUB



1-4th July, 2009
Szeged, Hungary

FINAL PROGRAMME



Sponsors of EPC 2009

The Organizing Committee of EPC 2009 is indebted to the following companies for their generous support:

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSOR



BRONZE SPONSOR



ADDITIONAL SPONSORS

MKB Bank Zrt.
Schering-Plough Hungary Kft.
3DHISTECH Kft.
Budapest Airport Minibusz Kft.

Sigma Aldrich Kft.
Auro Science Kft.
Institution of European Scientific Education and Research (ETOKI)
HUN-MED Kft. / FUJINON

TABLE OF CONTENTS

WELCOME	2
GENERAL INFORMATION	3
PROGRAMME OVERVIEW	21
SCIENTIFIC PROGRAMME	
Wednesday, 1 st July	23
Thursday, 2 nd July	25
Friday, 3 rd July	31
Saturday, 4 th July	37
POSTER SESSION I. P001-091	42
POSTER SESSION II. P092-177	51



WELCOME



Dear Colleagues,

On behalf of the Organizing Committee, I welcome you to the 41st Meeting of the European Pancreatic Club! First of all, **let me thank you for attending EPC2009.** We are delighted to have participants from more than 30 countries and are looking forward to a stimulating and interesting conference as the quality of submitted abstracts seems to be high. The oral and poster sessions are all designed to facilitate interaction with other basic and clinical scientists interested in pancreatology. Of the **278 abstracts**, 96 will be delivered as oral or oral / poster presentations. In addition, we will also have **47 state of the art lectures** delivered by top experts from all over the world. We are very happy that we could award all of the scholarship requests (124). Therefore, including the invited speakers, we could support the attendance of more than 170 scientists!

Hopefully, you will also enjoy the Social Events and an introduction to Hungarian Gastronomy during the Conference.

Szeged, your host city, is situated near Hungary's southeastern border on the banks of the river Tisza. It is home to around 170,000 people. Szeged is the main city of Csongrád county and serves as a commercial and cultural centre of the region. The climate is very pleasant and is well known for its sunny summers with temperatures ranging between 25-35 °C. Szeged gets an aver-

age of 2,000 hours of sunshine each year (that's 83.5 days of daylight), no wonder it's often called the **City of Sunshine**. Local industry is reputed for food processing and production. Szeged is especially famous for its two most prominent agricultural products: the Pick brand salami and one of the most distinctive Hungarian spices: the paprika. The paprika gets its red color and divine flavor from an extended exposure to sunlight, which makes Szeged an ideal place to grow this spice. Textiles, oil and natural gas processing, and clothing production are also of importance to the region. Theaters, cinemas, clubs, riverside swimming pools and sport grounds provide plenty of opportunities for recreation. There are several large parks and a famous botanical garden to stroll through. Fine restaurants are situated all over Szeged offering various national and international cuisines including Greek, Chinese, Italian, German, Indian, Transylvanian and Arabic. Public transportation which is in the form of streetcars, trolleybuses and buses is so extensive that you can virtually reach every corner of the city.

We hope that you will enjoy EPC2009 and the beauty of Szeged!

Best wishes,


Peter Hegyi, EPC President

GENERAL INFORMATION

EPC OFFICERS

PRESIDENT:	Peter Hegyi	Szeged, Hungary
PAST PRESIDENT:	Ewa Malecka-Panas	Łódz, Poland
PRESIDENT ELECT:	Johan Permert	Stockholm, Sweden
SECRETARY:	Helmut Friess	Munich, Germany
PAST SECRETARY:	Markus M. Lerch	Greifswald, Germany
TREASURER:	Rolf Graf	Zurich, Switzerland
PAST TREASURER:	Christoph Beglinger	Basel, Switzerland
COUNCIL MEMBERS:	Jolanta Jaworek	Krakow, Poland
	Marlène Dufresne	Toulouse, France
	Eithne Costello	Liverpool, UK
	Frank Ulrich Weiß	Greifswald, Germany
	Petr Dite	Brno, Czech Republic
	Xavier Molero	Barcelona, Spain
	Marco del Chiaro	Pisa, Italy
	David Fine	Southampton, UK

LOCAL ORGANIZERS

Zoltan Berger	Santiago, Chile
Laszlo Boros	Los Angeles, USA
Laszlo Czako	Szeged, Hungary
Gyula Farkas	Szeged, Hungary
Peter Hegyi	Szeged, Hungary
Attila Olah	Gyor, Hungary
Akos Pap	Budapest, Hungary
Zoltan Rakonczay Jr.	Szeged, Hungary
Miklos Sahin-Toth	Boston, USA
Tamas Takacs	Szeged, Hungary
Gabor Varga	Budapest, Hungary
Andras Varro	Szeged, Hungary
Viktoria Venglovecz	Szeged, Hungary
Tibor Wittmann	Szeged, Hungary

ABSTRACT SELECTION COMMITTEE**Basic Science**

Madhav Bhatia	Singapore, Singapore
Daniela Basso	Padova, Italy
Maria Vaccaro	Buenos Aires, Argentina
Minote Apte	Sydney, Australia

Clinical Science

Marc Besselink	Nieuwegein, The Netherlands
Jörg Kleeff	Munich, Germany
Pascal Hammel	Clichy, France
Davor Stimac	Rijeka, Croatia

PROFESSIONAL CONGRESS ORGANIZER

STAND-ART AGENCY Ltd.



Stand-Art Agency was established as a limited partnership in July 1996. Since 2004 the agency has been operating as a limited liability company. Their main area of activity is the organization of conferences for medical and healthcare professionals, but they also organize other events and cultural programs (concerts of classical music, and musical festivals). Owing to the co-ordinated work of a small group of professional staff - covering the separate tasks of billing, registration, and administration - they are successfully organizing conferences and other programs of high technical and professional standards.

Head of the company: Erika Bernath
Address: Szeged, Szatymazi u 7/A H - 6724
E-mail: stand-art@t-online.hu
Tel: +36 (62) 317-445
Fax: +36 (62) 317-445
Web: www.standartkonferencia.hu

**CONGRESS VENUE**

University of Szeged, József Attila Study and Information Centre (TIK)
6722 Szeged, Ady square 10

Language

The official language of the congress is English.

ON-SITE REGISTRATION FEES**MAIN MEETING, 1st - 3rd July 2009****FOR EPC MEMBERS**

Junior (<35 years) and/or East-European members and/or Basic Scientist	€ 290
Other members	€ 390

FOR PEOPLE WHO ARE NOT EPC MEMBERS

Junior (<35 years) and/or East-European members and/or Basic Scientist	€ 360
Other non-members	€ 490

ACCOMPANYING PERSONS

€ 95

Basic and Clinical Science Satellites, 4th July 2009

(for those attending the EPC Main Meeting)

FOR EPC MEMBERS

€ 30

FOR PEOPLE WHO ARE NOT EPC MEMBERS

€ 40

ACCOMPANYING PERSONS

€ 10

Basic and Clinical Science Satellites, 4th July 2009

(for those not attending the EPC Main Meeting)

€ 200

The registration fee for participants covers the following:

- admission to all scientific sessions
- a conference bag (including program leaflet and conference materials)
- coffee breaks, lunches and social events (latter are subject to a small registration fee (€ 2))
- free transport from and to Budapest Ferihegy Airport (available only before and after the meeting)
- discounted registration fee for the Satellite Symposiums

The registration fee for accompanying persons covers the following:

- social events (latter are subject to a small registration fee (€ 2))
- free transport from and to Budapest Ferihegy Airport (available only before and after the meeting)



Map of Szeged

- 1 HOTEL ALFA**
Szeged, Teréz u. 30
- 2 KATA PENSION**
Szeged, Bolyai u. 20
- 3 HOTEL ROYAL**
Szeged, Kölcsey F. u. 1-3
- 4 HOTEL KORONA**
Szeged, Petőfi Sugárút 4
- 5 BL LUXURY APARTMENT HOUSE**
Szeged, Szentháromság u. 48
- 6 FAMILIA PENSION**
Szeged, Szentháromság u. 71
- 7 MÁTYÁS PENSION**
Szeged, Dobó u. 47
- 8 TIK (CONGRESS VENUE)**
Szeged, Ady tér 10
- 9 TEKE & BOWLING SPORT MOTEL**
Szeged, Derkovits sugárút 1-5
- 10 HOTEL TISZA SPORT**
Szeged, Szent-Györgyi Albert u. 42
- 11 ILLÉS PENSION**
Szeged, Maros u. 37
- 12 TÍMÁRHÁZ PENSION**
Szeged, Maros u. 26
- 13 HOTEL NOVOTEL**
Szeged Maros u. 1
- 14 CITY HOTEL**
Szeged, Arany János u. 5
- 15 HOTEL TISZA**
Szeged, Széchenyi tér 3
- 16 DÓM HOTEL**
Szeged, Bajza u. 6
- GUESTHOUSE OF THE HUNGARIAN**
- 17 ACADEMY OF SCIENCES**
Szeged, Somogyi u. 7
- 18 APÁTHY RESIDENTIAL HALL**
Szeged, Apáthy u. 4
- 19 FEHÉRTÓI GUESTHOUSE**
Szeged, Budapesti út 41
- 20 ANNA BATH**
Szeged, Tisza Lajos krt. 24
- 21 CITY HALL**
Szeged, Széchenyi tér 10-11
- 22 NATIONAL THEATRE**
Szeged, Vaszy Viktor tér 1
- 23 NEW SYNAGOGUE**
Szeged, Gutenberg u. 20
- 24 VOTIVE CHURCH, OPEN-AIR THEATRE**
Szeged, Dóm tér 15
- 25 RAILWAY STATION**



REGISTRATION OPENING HOURS

Wednesday, 1 st July	9:00-19:00
Thursday, 2 nd July	7:30-18:00
Friday, 3 rd July	7:30-18:00
Saturday, 4 th July	7:30-12:00

Phone number of the registration desk:

REGISTRATION: Erika Bernath +36-30-372-5117

Any urgent questions outside the registration opening hours:

HEALTH: Peter Hegyi +36-70-375-1031
 TRANSPORT: Klaudia Farkas +36-20-416-6008
 ACCOMMODATION: Zita Varga +36-30-619-7348
 OTHER ISSUES: Zoltan Rakonczay +36-20-535-1309

NAME BADGES

Participants are requested to wear their name badges at all times.

WIRELESS INTERNET

There will be free wireless internet connection for the participants at TIK.
 Network: SZTE-EK , password is not required.

INTERNET POINTS

Several computers will be available at your convenience in the internet room.

TRANSPORT

Bus Transfer in Szeged:

We will organize a bus transfer service to TIK (the Congress Venue) from the hotels each morning (from Thursday to Saturday). A return service to the hotels will be available hourly from 10:00-19:00. The exact time-schedule of the buses will be posted in TIK and the hotels. Bus transfer will be also available for participants wanting to get to and from Social Events.



Bus Transfer from/to Budapest airport (Ferihegy)

The official bus transport company of EPC2009 is the **Airport Shuttle Ltd.** You will have to provide your flight details in advance to book transportation. **Please confirm your departure time and place (hotel, TIK, etc.) for your transfer back to the airport.** **PLEASE NOTE:** if you do not provide us these information in advance we cannot guarantee your transfer.

Taxi

Rádió Taxi is the official personal taxi company of the EPC2009 Congress. You can order a taxi by dialing +36-62-480-480. Conference participants will be entitled to discounted prices from 30th June - 5th July 2009. You must show the driver your name badge or Rádió Taxi card.

If you have any further requests regarding transport issues, please contact the Conference Registration Desk.

HEALTH AND SAFETY

Emergency Telephone numbers in Hungary

Ambulance: 104
 Police: 107
 Fire Department: 105


In case of any non-urgent health problems, we can help you out at the ER of the First Department of Medicine, University of Szeged (I. sz. Belgyógyászati Klinika, Szegedi Tudományegyetem). The address is: Korányi fasor 8-10. Telephone number: +36 (62) 545-198 or +36 (62) 545-813

PARKING IN SZEGED

Please be advised that in downtown of Szeged there are three different designated parking zones (green, yellow and blue). To park in these zones (indicated on the traffic signs), you will have to obtain a pre-paid parking ticket. This has to be displayed in a well-visible place, possibly behind the windscreen (from Monday to Friday, 8:00-18:00). The price of a parking ticket is HUF 340 (valid for 1 h in the green zone, for 2 h in the yellow zone and for 4 h in the blue zone). A daily parking ticket is also available for HUF 1240. **PLEASE NOTE that your car may be towed if you do not have a valid ticket.** Parking tickets can be bought at grocery stores, tobacconists and newsagents. We will also have some tickets available for you to purchase at the registration desk.


We will also have a limited number of parking places for conference participants in the parking garage of TIK. You must have your car registered beforehand at the registration desk.

MAP OF TIK (CONGRESS VENUE)




TIK – GROUND LEVEL

- 1. Conference registration desk and cloakroom
- 2. Exhibition area and congress buffet




TIK – ATRIUM

- 5. Poster session and congress lunch
- 6. Press-conference and VIP courtroom
- 7. Speaker Preview Center and internet room
- 8. Billing desk and financial issues
Accommodation affairs
Bus shuttle service



TIK – 1ST FLOOR

- 3. Congress Hall (Main Meeting and Basic Science Satellite)
- 4. Exhibition area and congress buffet



TIK – BASEMENT

- 11. Section Hall (Clinical Science Satellite on 4th July)

INVOICE ISSUES

Please note that we will only deal with invoice issues during lunch-time (13:10-14:20).

SPEAKER PREVIEW CENTRE

We will be providing a Speaker Preview Centre to presenters (see page 11 for location). All presenters are asked to check and hand in their presentation at the Speakers Preview Centre **at least 3 h prior to the lecture**. For morning sessions, please upload your presentation the day before.

SMOKING

Smoking is prohibited within TIK.

INSURANCE/LIABILITY

The Organizers of the EPC meeting and its satellites do not accept any liability for damages and or losses of any kind which may be incurred by conference participants or accompanying persons. Delegates participate at all events at their own risk.

TRAVEL SCHOLARSHIPS

124 Travel Scholarships have been awarded to young participants, Eastern Europeans and/or basic scientists. The Scholarship will **ONLY** be given to the presenting author attending the WHOLE main EPC meeting! Otherwise, the Scholarship will be revoked and the applicant will NOT receive the money! Therefore, **you must register before the start of the meeting**. The Scholarships can be collected at the billing desk on Friday between 16:00 and 19:00.

POSTER EXHIBITIONS

Posters are displayed on Thursday and Friday from 8:00-17:00. The authors of the posters are asked to put up their poster on the particular conference day between 7:30-8:00 and remove the posters between 17:00-17:30. Posters that have not been removed by 18:30 will be disposed of. At least one of the authors will be present during the poster session to answer questions.

BEST ABSTRACT AWARDS

The following awards will be presented at the Gala Dinner:

EPC RESEARCH PRIZE for the best **oral** presentation

EPC RESEARCH PRIZE for the best **poster** presentation

SOLVAY RESEARCH PRIZE for the best abstract in **pancreatitis** (basic science)

AXCAN-SAGER RESEARCH PRIZE for the best abstract in **pancreatitis** (clinical science)

OLYMPUS RESEARCH PRIZE for the best abstract in **pancreatic cancer** (clinical science)

HIRSHBERG-SIDMAP RESEARCH PRIZE for the best abstract in **pancreatic cancer** (basic science)

RICHTER RESEARCH PRIZE for the best abstract in **pancreatic physiology** (basic science)

ACKNOWLEDGEMENTS

The local organizers would like to thank Professors Ole Petersen (University of Liverpool, UK) and Markus Lerch (University of Greifswald, Germany) for their help in putting together the Scientific Program.

SOCIAL EVENTS

Welcome Party - Folkdance Evening (National Theatre Szeged, 1st July 20:00)

Varnus Xaver Organ Concert (New Synagogue, 2nd July 20:30)

Faculty evening at the City Hall – ONLY by invitation (City Hall, 2nd July 18:40)

Gala Dinner - Csilla Szentpeteri Piano Concert (Hotel Tisza, 3rd July 20:30)

Buffet Dinner at Anna Bath (Anna Bath, 4th July 19:00)

See additional leaflet.

ACCOMPANYING PERSONS PROGRAMME

Guided sightseeing tour in Szeged by bus (Departure: TIK Szeged, 1st July 10:00)

Guided sightseeing tour by bus to Budapest (Departure: TIK Szeged, 2nd July 8:30)

Guided tour by bus to the National Historical Memorial Park (Departure: TIK Szeged, 3rd July 9:30)

Pleasure trip by boat on Tisza river (Departure: TIK Szeged, 4th July 10:30)

Open Air Festival - "Gipsy Love" light opera (Dom square, 4th July 21:00)

EXHIBITORS

Solvay Pharmaceuticals

AXCAN Pharma / SAGER Pharma

City of Szeged

Richter Gedeon Nyrt.

Olympus Hungary Kft.

Sidmap / Hirshberg Foundation

Berlin-Chemie / A. Menarini Hungary Kft.

3DHISTECH Kft.

HUN-MED Kft. / FUJINON

Cancer Research UK Liverpool Cancer Trials Unit - University of Liverpool Cancer Research Centre

First

visit the Tourinform Office

OUR SERVICES

Tourist information on Szeged and Hungary
(Programmes, accommodations, monuments, museums, natural values, etc.)

Tourist publications about Hungary
(in Hungarian and other languages)

DVD, CD about Hungary
(in Hungarian and other languages)

Hungary Card

Postcards, maps of Szeged

Concert and theatre tickets

Sightseeing in Szeged


Tourist guides

Rent a bike



Tourinform Szeged
Dugonics tér 2.
H-6720 Szeged, Hungary
Tel.: +36-62/488-699
Tel./Fax: +36-62/488-690
e-mail: szeged@tourinform.hu

www.szeged.eu



**Sunshine and water,
the living elements of Szeged,
the city of science**

Anything considered the conditions of prosperous life, can all be found in Szeged. The Creator gave very generously sunshine and water here. Near the city, situated at the mouth of the River Tisza and the River Maros, the flora and fauna of the shallow deflation lakes are wonderful. Lake Fehér has 250 registered bird species. The flora of the sodic plains amaze ornithologists and nature-lover tourists. The medical water coming from the depth thanks to human intervention has beneficial influence. The backwaters and artificial lakes created after the regulation of the River Tisza are the paradise for fishers.

Szeged is the capital of water sports, kayak-canoe and rowing. The National Kayak-Canoe and Rowing Olympic Center holds several world competitions every year. Albert Szent-Györgyi, physiologist, carried out his researches in Szeged. He was awarded the Nobel Prize in Physiology or Medicine in 1937 for the production of vitamin C. At the University of Szeged, at its 12 departments, with the leadership of famous professors, educational, research and medicinal works are carried in Hungarian and in several foreign languages, whose real winners are the students from all over the world, who embody the intellectual industry of the future.

tourinform
Turista információ • Tourist Information

Információ:
www.szegedvaros.hu
www.szeged.eu

 **Panzylrat®**

Targeted precision



Indicated for*:

- Exocrine pancreatic insufficiency.
- Cystic fibrosis enzyme substitution therapy.

* Please refer to the approved labeling in your respective country.

** Please refer to the approved strengths in your respective country.

AXCAN PHARMA

Pompás

- IC Ca, pH, membránpotenciál mikroszkópon/microplate readeren
- Patch Clamp/HTS
- Extracelluláris elvezetések (in vitro) heteken keresztül: MEA rendszerek
- Új Nikon swept field confocal mikroszkóp
- Sanyo fagyasztók, CO₂ inkubátorok, autoklávok stb.)
- Genotypizálás (IMAP és AlphaScreen)
- Új Hitachi fluoriméter

Az Auro-Science Kft.

várja az érdeklődőket!

Látogasson el hozzánk a www.auroscience.hu honlapra és irodánkba
Nikon, Sanyo, Hitachi, Till-Photonics, Multichannel Systems, BMG
Labtech termékeink várják Önöket türelmesen

AURO-SCIENCE CONSULTING KFT.

1031 Budapest, Drótos u. 1. • Telefon: (36-1) 242-1390 • Telefax: (36-1) 242-1391

E-mail: info@auroscience.hu

Web: www.auroscience.hu

FACULTY OF THE EPC 2009

ALHONEN, L (Kuopio, Finland)	MAYERLE, J (Greifswald, Germany)
BASSI, C (Verona, Italy)	McKAY, C (Glasgow, Scotland)
BASSO, D (Padova, Italy)	MOLERO, X (Barcelona, Spain)
B EGLINGER, C (Basel, Switzerland)	MORISSET, J (Sherbrooke, Canada)
BOROS, L (Los Angeles, USA)	MUALLEM, S (Dallas, USA)
BUCHLER, MW (Heidelberg, Germany)	MÖSSNER, J (Leipzig, Germany)
BUSCAIL, L (Toulouse, France)	NEOPTOLEMOS, J (Liverpool, UK)
CHANDAK, GR. (Hyderabad, India)	NORDBACK, I (Tampere, Finland)
CHARNLEY, R (Newcastle, UK)	OLAH, A (Gyor, Hungary)
CRIDDLE, D (Liverpool, UK)	O'KEEFE, SJ (Pittsburgh, USA)
DERVENIS, C (Athens, Greece)	OTSUKI, M (Kitakyushu, Japan)
DITE, P (Brno, Czech Rep.)	PANDOL, S (LA, USA)
DUFRESNE, M (Toulouse, France)	PAP, A (Budapest, Hungary)
FEREC, C (CHU de Brest, France)	PERMERT, J (Stockholm, Sweden)
FRIESS, H (Munich, Germany)	PETERSEN, O (Liverpool, UK)
GALIONE, A (Oxford, UK)	PETRONJIEVIC, L (Belgrad, Serbia)
GERASIMENKO, J (Liverpool, UK)	RAKONCZAY JR., Z (Szeged, Hungary)
GIOVANNINI, M (Marseille, France)	RAU, BM (Rostock, Germany)
GO, VLW (Los Angeles, USA)	SAHIN-TOTH, M (Boston, USA)
GORELICK, F (New Haven, USA)	SALUJA, A (Minneapolis, USA)
GRAF, R (Zurich, Switzerland)	SANDBERG, A (Stockholm, Sweden)
GRAY, M (Newcastle, UK)	SCHMID, R (Munich, Germany)
GRESS, T (Marburg, Germany)	SEUFFERLEIN, T (Halle, Germany)
GRIESBACHER, T (Graz, Austria)	SHEPPARD, DN (Bristol, UK)
GUKOVSKAYA, A (Los Angeles, USA)	SOLEIMANI, M (Cincinnati, USA)
GUKOVSKY, I (Los Angeles, UK)	SPAT, A (Budapest, Hungary)
HALANGK, W (Magdeburg, Germany)	TAKACS, T (Szeged, Hungary)
HAMMEL, P (Clichy, France)	TEPIKIN, A (Liverpool, UK)
ISHIGURO, H (Nagoya, Japan)	THORN, P (Brisbane, Australia)
JAWOREK, J (Krakow, Poland)	UOMO, G (Napoli, Italy)
LANKISCH, P (Lüneburg, Germany)	URRUTIA, R (Rochester, USA)
LEE, MG (Seoul, Korea)	VACCARO, M (Buenos Aires, Argentina)
LERCH, M (Greifswald, Germany)	VARGA, G (Budapest, Hungary)
LEVY, P (Clichy, France)	VENGLOVECZ, V (Szeged, Hungary)
LÖHR, M (STOCKHOLM, SWEDEN)	WHITCOMB, DC (Pittsburg, USA)
MACEK, M (PRAGUE, CZECH REPUBLIC)	WITT, H (Berlin Germany)
MALECKA-PANAS, E (LLODZ, POLAND)	

PROGRAMME OVERVIEW

Wednesday, July 1, 2009 - MAIN MEETING DAY1


09.00 - 13.00	Registration
13.00 - 13.10	OPENING OF THE MEETING
13.10 - 15.01	SESSION I. TRANSLATIONAL RESEARCH (BENCH TO THE BEDSIDE)
15.01 - 15.20	Coffee break
15.20 - 17.11	SESSION II. TRANSLATIONAL RESEARCH (BEDSIDE TO THE BENCH)
17.11 - 17.30	Coffee break
17.30 - 17.55	INTRODUCTION OF GWAS
20.00 -	Welcome party

Thursday, July 2, 2009 - MAIN MEETING DAY2

06.30 - 08.30	EPC COUNCIL MEETING (Hotel Novotel)
08.00 - 09.50	SESSION III. ACUTE PANCREATITIS 1.
09.50 - 10.10	Coffee break
10.10 - 11.40	SESSION IV. ACUTE PANCREATITIS 2.
11.50 - 13.10	ORAL-POSTER SESSION
13.10 - 14.20	Lunch time
13.10 - 14.20	POSTER SESSION I. P001-091
13.30 - 14.15	EUROPAC SATELLITE MEETING
14.20 - 15.45	SESSION V. INITIATION OF PANCREATITIS, EARLY EVENTS
15.45 - 16.05	Coffee break
16.05 - 17.42	SESSION VI. CHRONIC PANCREATITIS
18.40	Faculty evening at the City Hall (invitation by the mayor)
20.30	Organ concert by Xaver Varnus

Friday, July 3, 2009 - MAIN MEETING DAY3

08.00 - 09.49	SESSION VII. PANCREATIC CANCER / SURGERY
09.49 - 10.00	Coffee break
10.00 - 11.40	SESSION VIII. CANCER
11.50 - 13.10	ORAL-POSTER SESSION
13.10 - 14.30	Lunch time
13.10 - 14.20	POSTER SESSION II. P092-177
13.20 - 13.40	Raise or Blast Hopes: TREATMENT OF PANCREATIC CANCER
13.40 - 14.25	ESPAC SATELLITE MEETING
14.30 - 16.19	SESSION IX. GENETICS
16.19 - 16.30	Coffee break



16.30 - 18.10	SESSION X.	BASIC SCIENCE
18.10 - 19.10	GENERAL ASSEMBLY	
20.30	Gala Dinner	

SATURDAY, July 4, 2009 - POSTGRADUATE COURSE AND BASIC SATELLITE

07.30 - 12.00	Registration	
08.00 - 08.05	OPENING OF THE MEETING	
08.05 - 08.20	Pre-Meeting Test	
08.30 - 10.05	SATELLITE I.	PANCREATIC ACINI 1
10.05 - 10.25	Coffee break	
10.25 - 12.00	SATELLITE II.	PANCREATIC ACINI 2
12.00 - 13.00	Lunch time	
13.00 - 14.35	SATELLITE III.	GENETIC BASIS OF PANCREATITIS
14.35 - 14.50	Coffee break	
14.50 - 16.05	SATELLITE IV.	PANCREATIC DUCTS 1
16.05 - 16.25	Coffee break	
16.25 - 18.00	SATELLITE IV.	PANCREATIC DUCTS 2
18.00 - 18.15	Post-Meeting Test	
19.00	Social program (Buffet dinner and wellness at Anna Bath)	
21.00	Optional Social program (Open-Air Theatre)	

SATURDAY, July 4, 2009 - POSTGRADUATE COURSE AND CLINICAL SATELLITE

07.30 - 12.00	Registration	
09.00 - 09.05	OPENING THE MEETING	
09.05 - 09.20	Pre-Meeting Test	
09.00 - 10.40	SATELLITE I.	ENDOSCOPY
10.40 - 11.00	Coffee break	
11.00 - 12.00	SATELLITE II.	ENTERAL FEEDING AND NUTRITION
12.00 - 13.00	Lunch time	
13.00 - 14.20	SATELLITE III.	SURGERY
14.20 - 14.40	Coffee break	
14.40 - 15.45	SATELLITE IV.	GUIDELINES
15.45 - 16.00	Post-Meeting Test	
19.00	Social program (Buffet dinner and wellness at Anna Bath)	
21.00	Optional Social program (Open-Air Theatre)	

Scientific Programme

Wednesday,

1st July, 2009

MAIN MEETING
DAY 1

09.00-13.00 REGISTRATION

13.00-13.10 OPENING OF THE MEETING

GABOR SZABO Rector of the University of Szeged
GYORGY BENEDEK Dean of the Faculty of Medicine, University of Szeged

13.10-15.01 SESSION I. TRANSLATIONAL RESEARCH (BENCH TO THE BEDSIDE)

Chairs: MARKUS LERCH (Greifswald, Germany), JEAN MORISSET (Sherbrooke, Canada)

13.10 STATE OF THE ART LECTURE 1

OLE PETERSEN (Liverpool, UK): CHANGES OF PANCREATIC ACINAR CELL FUNCTION IN PANCREATITIS.

13.35 STATE OF THE ART LECTURE 2

SHMUEL MUALLEM (Dallas, USA): THE VARIOUS TRANSPORT MODES OF THE SLC26 TRANSPORTERS.

14.00 STATE OF THE ART LECTURE 3

ASHOK SALUJA (Minneapolis, USA): HOW DO IN VIVO PANCREATITIS MODELS HELP US TO UNDERSTAND CLINICAL QUESTIONS IN ACUTE PANCREATITIS?

14.25 O-1

G. Telek, T. Sztipits, J. Fent, J. Regoly-Merei: ACTIVATION INDUCED DYSFUNCTION OF LEUKOCYTES-MAY CONTRIBUTE TO THE IMMUNE DEFICIENT STATE CHARACTERIZING THE CARS IN HUMAN ACUTE PANCREATITIS.

14.37 O-2

R. Szmola, M. Sahin-Toth: A CHRONIC PANCREATITIS-ASSOCIATED CHYMOTRYPSINOGEN C (CTRC) MUTANT ELICITS ENDOPLASMIC RETICULUM STRESS IN PANCREATIC ACINAR CELLS.

14.49 O-3

F. U. Weiss, I. J. Marques, J. M. Woltering, D. H. Vlecken, A. Aghdassj, L. I. Partecke, C. D. Heidecke, M. M. Lerch, C. P. Bagowski: RETINOIC ACID RECEPTOR (RAR) ANTAGONISTS INHIBIT MIR-10A EXPRESSION AND PREVENT METASTATIC BEHAVIOUR OF PANCREATIC CANCER.



15.20 STATE OF THE ART LECTURE 4

MARKUS W. BUCHLER (Heidelberg, Germany): CLINICAL QUESTIONS IN CHRONIC PANCREATITIS: PAIN.

15.45 STATE OF THE ART LECTURE 5

FRED GORELICK (New Haven, USA): THERAPEUTIC TARGETS IN ACUTE PANCREATITIS.

- 16.10 STATE OF THE ART LECTURE 6**
PASCAL HAMMEL (Clichy, France): **NEW INSIGHTS IN PANCREATIC CANCERS.**
- 16.35 O-4**
D. Whitcomb, V. Muddana, C. Langmead, F. Houghton, A. Guenther, P. Eagon, J. Mayerle, A. Aghdassi, F. U. Weiss, J. Lamb, G. Clermont, M. Lerch, G. Papachristou: **ANGIOPOIETIN-2, A REGULATOR OF VASCULAR PERMEABILITY IN INFLAMMATION, IS ELEVATED IN SEVERE ACUTE PANCREATITIS AND IS ASSOCIATED WITH SYSTEMIC ORGAN FAILURE IN PATIENTS FROM PITTSBURGH, PA AND GREIFSWALD, GERMANY.**
- 16.47 O-5**
M. Luaces, J. Iglesias-Garcia, M. Castiñeira, J. Larino-Noia, J. E. Dominguez-Munoz: **SERUM FRACTALKINE LEVELS AS MARKER OF MORPHOLOGICAL PROGRESSION OF CHRONIC PANCREATITIS: A PROSPECTIVE STUDY WITH THREE YEAR FOLLOW-UP.**
- 16.59 O-6**
B. Bournet, A. Souque, F. Muscari, P. Senesse, E. Assenat, M. Barthet, N. Lesavre, A. Aubert, D. O'Toole, P. Hammel, P. Levy, P. Ruzniewski, J. Escourrou, R. Guimbaud, P. Cordelier, L. Buscail: **PROGNOSIS IMPACT OF KRAS MUTATION ON LOCALLY ADVANCED AND/OR METASTATIC PANCREATIC CANCER PATIENTS TREATED OR NOT WITH CHEMOTHERAPY: A PROSPECTIVE MULTICENTER STUDY.**



17.30-17.55 INTRODUCTION OF GWAS

Chairs: DEREK O'REILLY (Manchester, UK), HEIKO WITT (Munich, Germany)

- 25 min.** JOOST PH DRENTH (Nijmegen, The Netherlands): **A PAN EUROPEAN INITIATIVE FOR A GENOME WIDE SCAN IN ALCOHOLIC CHRONIC PANCREATITIS.**
- 20:00 WELCOME PARTY - SZEGED NATIONAL THEATRE**
Address: Szeged, Vaszy Viktor tér 1
- 20:00-20:30 ARRIVAL, WELCOME DRINK**
- 20:30 OPENING OF THE SOCIAL EVENTS**
LASZLO BOTKA - Mayor of Szeged
- 20:40 FOLKDANCE EVENING**
- 21:30 DINNER**



Scientific Programme

Thursday,

2nd July, 2009

MAIN MEETING
DAY2

06.30-08.30 EPC COUNCIL MEETING
Hotel Novotel (Address: Szeged, Maros u. 1.)

08.10-09.50 SESSION III. ACUTE PANCREATITIS 1.

Chairs: BETTINA M. RAU (Rostock, Germany), MARIA VACCARO (Buenos Aires, Argentina)

- 08:00 STATE OF THE ART LECTURE 7**
STEPHEN PANDOL (Los Angeles, USA): **PATHOPHYSIOLOGY AND PATHOBIOLOGY OF ALCOHOL INDUCED PANCREATIC DISEASES.**
- 08:25 O-7**
O. J. Bakker, H. C. van Santvoort, J. C. Hagenaars, T. L. Bollen, M. G. Besselink, H. G. Gooszen, A., F. Schaapherder: **TIMING OF CHOLECYSTECTOMY IN 418 PATIENTS WITH MILD AND SEVERE BILIARY PANCREATITIS: DUTCH MULTICENTER EXPERIENCE.**
- 08:37 O-8**
B. Stepień, G. Rydzewska, D. Baczewska-Mazurkiewicz, J. Rutkowska, W. Olszewski, Z. Czapnik, A. Rydzewski: **TNF α , TNF β , CD14, CCR2 AND TLR2 POLYMORPHISMS IN PATIENTS WITH ACUTE PANCREATITIS (AP).**
- 08:49 O-9**
P. G. Lankisch, B. Weber-Dany, P. Maisonneuve, A. B. Lowenfels: **PANCREATIC PSEUDOCYSTS: PROGNOSTIC FACTORS FOR THEIR DEVELOPMENT AND THEIR SPONTANEOUS RESOLUTION.**
- 09:01 O-10**
J. Trna, S. S. Vege, V. Pribramska, S. T. Chari, P. S. Kamath: **RECURRENCE OF ACUTE PANCREATITIS AFTER CHOLECYSTECTOMY: A POPULATION-BASED STUDY.**
- 09:13 O-11**
E. de-Madaria, G. Soler, J. Martinez, L. Gomez-Escolar, C. Sanchez-Fortun, L. Sempere, I. Lopez-Font, J. Perez, M. Perez-Mateo: **UPDATE OF THE ATLANTA CLASSIFICATION OF SEVERITY OF ACUTE PANCREATITIS: SHOULD A MODERATE CATEGORY BE INCLUDED?**
- 09:25 O-12**
R. Talukdar, S. S. Vege, S. Chari, M. Clemens, R. Pearson: **MODERATELY SEVERE ACUTE PANCREATITIS: A PROSPECTIVE VALIDATION STUDY OF THIS NEW SUBGROUP OF ACUTE PANCREATITIS.**
- 09:37 O-13**
H. C. van Santvoort, O. J. Bakker, M. G. Besselink, T. L. Bollen, K. Fischer, H. Gooszen, K. J. van Erpecum: **PREDICTORS OF COMMON BILE DUCT STONES DURING EARLY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATICOGRAPHY IN ACUTE BILIARY PANCREATITIS.**



10.10-11.35 SESSION IV. ACUTE PANCREATITIS 2.

Chairs: DANIEL CLOSA (Barcelona, Spain), WALTER HALANGK (Magdeburg, Germany)

10.10 STATE OF THE ART LECTURE 8

ZOLTAN RAKONCZAY (Szeged, Hungary): AMINO ACID-INDUCED EXPERIMENTAL PANCREATITIS.

10.35 O-14

G. Uomo, F. Gallucci, E. Madrid, S. Miraglia, G. Manes, P. G. Rabitti: PANCREATIC FUNCTIONAL IMPAIRMENT FOLLOWING ACUTE NECROTIZING PANCREATITIS: LONG TERM OUTCOME OF NON-SURGICALLY TREATED SERIES.

10.47 O-15

D. Grasso, A. Ropolo, V. Boggio, A. E. Lo Re, R. Pardo, J. L. Iovanna, M. I. Vaccaro: VACUOLE-MEMBRANE-PROTEIN-1 MEDIATED AUTOPHAGY PREVENTS SEVERE EFFECTS OF ACUTE PANCREATITIS IN TRANSGENIC MICE.

10.59 O-16

O. A. Mareninova, M. A. Lee, I. Yakubov, S. J. Pandol, S. W. French, F. S. Gorelick, I. Gukovsky, A. S. Gukovskaya: AUTOPHAGY IMPAIRMENT AS A MECHANISM FOR ACUTE PANCREATITIS: THE ROLE OF CATHEPSINS.

11.11 O-17

M. Sendler, J. Mayerle, A. Dummer, F. U. Weiss, B. Brandt-Nedelev, K. Scharffetter-Kochanek, N. van Rooijen, W. Halangk, M. M. Lerch: TRANSMIGRATING LEUKOCYTES MEDIATE PROTEASE ACTIVATION IN ACUTE PANCREATITIS VIA TNF SECRETION.

11.23 O-18

D. Closo, S. Gea-Sorlí, N. Franco-Pons: ADIPOSE TISSUE INFLAMMATION EXACERBATES THE TOXICITY OF FAT NECROSIS IN ACUTE PANCREATITIS.

10.50-13.10 ORAL-POSTER SESSION

Chairs: JOHAN PERMERT (Stockholm, Sweden), AKOS PAP (Budapest, Hungary), GINO SACCONI (Adelaide, Australia)

11.50 OP-1

J. Mayerle, B. Krüger, N. K. Karanam, F. U. Weiss, U. Völker, M. Zenker, M. M. Lerch: THE GTPASE ACTIVATING PROTEIN RGS4 MEDIATES PANCREATIC DAMAGE IN JOHANSON-BLIZZARD SYNDROME.

11.54 OP-2

Z. Dambrauskas, A. Parselionas, A. Gulbinas, A. Dauksa, G. Barauskas, J. Pundzius: EARLY RECOGNITION OF ABDOMINAL COMPARTMENT SYNDROME IN PATIENTS WITH ACUTE PANCREATITIS.

11.58 OP-3

A. Szabolcs, G. Biczó, L. Tiszlavicz, Z. Rakonczay, T. Wittmann, T. Takacs: BORTEZOMIB TREATMENT INTERFERES WITH IB DEGRADATION AND INDUCES HSP SYNTHESIS IN EXPERIMENTAL ACUTE NECROTIZING PANCREATITIS.

12.02 OP-4

Q. M. Nunes, J. Gardner-Thorpe, K. Dajani, M. Raraty, P. Ghaneh, R. Sutton, J. P. Neoptolemos: CRP AS AN INDICATOR FOR USING CT-GUIDED FINE NEEDLE ASPIRATION IN THE DIAGNOSIS OF INFECTED PANCREATIC NECROSIS.

12.06 OP-5

A. Schneider, J. Steih, D. Moßler, R. H. Pfützner, J. M. Löhr, M. V. Singer: FREQUENCY OF AUTOIMMUNE PANCREATITIS (AIP) IN PATIENTS WITH ACUTE AND CHRONIC PANCREATITIS FROM GERMANY.

12.10 OP-6

B. Lindkvist, S. Appelros, S. Regner, J. Manjer: SERUM CALCIUM LEVELS WITHIN NORMAL RANGE ARE NOT ASSOCIATED WITH THE RISK FOR ACUTE PANCREATITIS. REPORT FROM A PROSPECTIVE COHORT STUDY.

12.14 OP-7

R. Mukherjee, W. Huang, D. Booth, G. Rosenberg, J. Friedman, A. Tepikin, O. Petersen, B. Azadeh, D. Criddle, R. Sutton: THE NOVEL LIPOPHILIC CHELATOR DP-B99 DECREASES CYTOSOLIC CA²⁺ AND SEVERITY OF CAERULEIN-INDUCED PANCREATITIS.

12.18 OP-8

D. Stimac, I. Krznaric-Zrnica, S. Milic, L. Bilic-Zulle, E. Fisić: COMPUTED TOMOGRAPHY SEVERITY INDEX IS THE BEST PREDICTOR OF ACUTE PANCREATITIS SEVERITY.

12.22 OP-9

A. Dembinski, Z. Warzecha, P. Ceranowicz, J. Cieszkowski, B. Kusnierz-Cabala, R. Tomaszewska: ROLE OF GROWTH HORMONE AND IGF-1 IN HEALING EFFECTS OF GHRELIN IN CERULEIN-INDUCED ACUTE PANCREATITIS.

12.26 OP-10

T. Varkonyi, A. Szabolcs, V. Szidor, A. Szasz, E. Borsok, C. Lengyel, P. Kempler, T. Takacs, T. Wittmann: ASSESSMENT OF THE FREQUENCY AND THE CONSEQUENCES OF IMPAIRED EXOCRINE PANCREATIC FUNCTION IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES.

12.30 OP-11

J. Bonior, J. Jaworek, S. J. Konturek, W. W. Pawlik: LEPTIN INDUCES ACTIVATES APOPTOTIC PATHWAYS IN PANCREATIC AR42J.

12.34 OP-12

M. C. Chang, S. C. Wei, P. C. Liang, I. S. Jan, Y. N. Su, C. H. Kuo, J. M. Wong, Y. T. Chang: ASSOCIATION OF NOVEL CHYMOTRYPSIN C (CTRC) GENE VARIATIONS AND HAPLOTYPES IN PATIENTS WITH CHRONIC PANCREATITIS IN CHINESE IN TAIWAN.

- 12.38 OP-13**
G. Sauter, M. Sahin-Toth, P. Simon, S. Teller, M. M. Lerch, F. U. Weiss: IDENTIFICATION OF A NEW N2K TRYPSINOGEN (PRSS1) MUTATION – POSSIBLE ASSOCIATION WITH IDIOPATHIC OR HEREDITARY PANCREATITIS.
- 12.42 OP-14**
K. Uchida, H. Miyoshi, T. Kusuda, M. Koyabu, N. Fukata, Y. Sakaguchi, T. Ikeura, T. Fukui, M. Matsushita, M. Takaoka, K. Okazaki: REGULATORY T CELLS IN PATIENTS WITH AUTOIMMUNE PANCREATITIS.
- 12.46 OP-15**
G. Z. Racz, E. Bori, I. Demeter, S. Qi, G. Varga: INCREASED FLUID SECRETION AFTER ADENOVIRAL-MEDIATED TRANSFER OF HUMAN AQUAPORIN-1 CDNA TO PARC10 EPITHELIA: IMPLICATIONS FOR GENE THERAPY.
- 12.50 OP-16**
R. Jesenovskiy, W. Hagmann, M. Löhr: GENISTEIN DEACTIVATES IMMORTAL PANCREATIC STELLATE CELLS.
- 12.54 OP-17**
M. Luaces, J. Iglesias-Garcia, M. Castiñeira, J. Larino-Noia, L. Nieto, A. Lozano-Leon, A. Alvarez-Castro, R. Gomez-Casal, J. E. Dominguez-Munoz: FACTORS ASSOCIATED TO THE SEVERITY OF CHRONIC PANCREATITIS AT DIAGNOSIS: ALCOHOL, TOBACCO, OR BOTH?
- 12.58 OP-18**
I. E. Demir, G. Ceyhan, U. Rauch, M. Müller, K. Schäfer, H. Friess: THE MICROENVIRONMENT IN CHRONIC PANCREATITIS AND PANCREATIC CANCER INDUCES NEURONAL PLASTICITY
- 13.02 OP-19**
H. Lee, Y. Cho, Y. Choi, H. Yim, S. Lee, J. Choi, C. Kim: THE EFFECT OF HMG-COA REDUCTASE INHIBITOR ON LIPOPOLYSACCHARIDE INDUCED ACTIVATION OF PANCREATIC STELLATE CELLS.
- 13.06 OP-20**
Y. Le Baieur, V. Rebours, D. Cazals-Hatem, Y. Bouhnik, P. Bédossa, P. Ruszniewski, P. Lévy, A. Couvelard: IGG4 POSITIVE PLASMA CELL INFILTRATION IN THE DIGESTIVE TRACT MUCOSA OF PATIENTS WITH AUTOIMMUNE PANCREATITIS IS NEITHER ABUNDANT NOR SPECIFIC.



13.10-14.20 POSTER SESSION I. (SEE PAGE 42)
P001-091

13.10-14.15 EUROPAC SATELLITE MEETING Organizer: JULIA MAYERLE
Chairs: JULIA MAYERLE (Greifswald, Germany), **WILLIAM GREENHALF** (Liverpool, UK)

Jane Butler (Liverpool, UK): HIGH RISK FAMILIES: QUANTIFICATION OF PANCREATIC CANCER RISK.
Matt Harcus (Liverpool, UK): UPDATE ON THE EUROPAC REGISTRY.
Vinciane Rebours (Clichy, France): THE PATTERN OF HEREDITARY PANCREATITIS IN FRANCE.
Julia Mayerle and Marcus Lerch (Greifswald, Germany): UPDATE ON EUROPAC2.

14.20-15.45 SESSION V. INITIATION OF PANCREATITIS, EARLY EVENTS
Chairs: MIKLOS SAHIN-TOTH (Boston, USA), **ALEXEI TEPIKIN** (Liverpool, UK)

14:20 STATE OF THE ART LECTURE 9

MARKUS LERCH (Greifswald, Germany): EARLY EVENTS IN ACUTE PANCREATITIS.

14:45 O-19

D. Booth, O. Petersen, R. Sutton, D. Criddle: ROLE OF ETHANOL METABOLISM IN PANCREATIC ACINAR CELL DEATH.

14:57 O-20

T. Wartmann, B. Brandt-Nedelev, S. Ravi Malla, J. Mayerle, M. M. Lerch, W. Halang: LATE, BUT NOT EARLY TRYPSINOGEN ACTIVATION IN CAERULEIN-INDUCED MOUSE PANCREATITIS DEPENDS ON AUTOPHAGY AND OCCURS IN AUTOPHAGOLYSOSOMES.

15:09 O-21

S. P. Jaya, A. Schloithe, C. Carati, J. Toouli, G. Saccone: GALANIN STIMULATES PANCREATIC SECRETION VOLUME AND INHIBITS AMYLASE SECRETION IN THE ANAESTHETISED AUSTRALIAN POSSUM.

15:21 O-22

M. Hirota, M. Ohmuraya, D. Hashimoto, K. Yamamura, H. Baba: AUTOPHAGY PROCESS ACTIVATES TRYPSINOGEN AND TRIGGERS THE DEVELOPMENT OF ACUTE PANCREATITIS.

15:33 O-23

J. Maleth, Z. Rakonczay, V. Venglovecz, Z. Razga, L. Tiszlavicz, P. Hegyi: CHENODEOXYCHOLATE INDUCES MITOCHONDRIAL DAMAGE IN PANCREATIC DUCTAL EPITHELIAL CELL.



16.05-17.42 SESSION VI. CHRONIC PANCREATITIS

Chairs: LASZLO CZAKO (Szeged, Hungary), **PAUL G. LANKISCH** (Lüneburg, Germany)

16:05 STATE OF THE ART LECTURE 10

MAKOTO OTSUKI (Kitakyushu, Japan): METABOLIC COMPLICATIONS OF CHRONIC PANCREATITIS.

- 16:30** **O-24**
G. Farkas, L. Leindler, M. Daroczi, G. Farkas: 10-YEAR EXPERIENCE WITH DUODENUM AND ORGAN-PRESERVING PANCREATIC HEAD RESECTION (BERNE-FARKAS MODIFICATION) IN THE SURGICAL TREATMENT OF CHRONIC PANCREATITIS.
- 16:42** **O-25**
J. Iglesias-Garcia, J. Larino-Noia, L. Nieto, F. Macías, S. Seijo, A. Alvarez-Castro, C. Villalba, J. E. Dominguez-Munoz: CHRONIC PANCREATITIS: A FREQUENT CAUSE OF PAIN-PREDOMINANT DYSPEPSIA.
- 16:54** **O-26**
A. Schneider, P. Maisonneuve, J. M. Löhr, M. V. Singer: FIRST APPROACH TO VALIDATE THE MANNHEIM CLASSIFICATION SYSTEM OF CHRONIC PANCREATITIS BY CLINICAL CATEGORIZATION OF 523 PATIENTS.
- 17:06** **O-27**
A. Molven, M. Vesterhus, B. B. Johansson, J. Torsvik, K. Fjeld, I. Haldorsen, S. Johansson, A. Ragvin, H. Ræder, R. Kulkarni, C. R. Kahn, P. R. Njølstad: EXOCRINE PANCREATIC DYSFUNCTION AND DIABETES CAUSED BY CEL MUTATIONS: TOWARDS A DISEASE MECHANISM.
- 17:18** **O-28**
A. M. González, M. Guilà, M. Rickmann, E. C. Vaquero, X. Molero: BIOCHEMICAL AND MORPHOLOGICAL ASSESSMENT OF THE BENEFITS OF PALM OIL TOCOTRIENOL RICH FRACTION ON ARGININE-INDUCED CHRONIC-LIKE PANCREATITIS.
- 17:30** **O-29**
M. Rickmann, J. M. Roig, A. González, M. Guilà, X. Molero, E. C. Vaquero: TOCOTRIENOLS INDUCE PANCREATIC STELLATE CELL (PSC) DEATH BY COMPETING WITH UBIQUINONE AT THE MITOCHONDRIA, INDEPENDENTLY OF ITS PRO-OXIDATIVE EFFECTS.
- 18:40** **FACULTY EVENING AT THE CITY HALL (INVITATION BY THE MAYOR)**
Address: Szeged, Szechenyi tér 10-11
- 20:30** **ORGAN CONCERT BY VARNUS XAVER - NEW SYNAGOGUE**
Address: Szeged, Gutenberg u. 20



Scientific Programme

Friday,

3rd July, 2009

MAIN MEETING
DAY 3

08.00-09.49 SESSION VII. PANCREATIC CANCER / SURGERY

Chairs: LASZLO BOROS (Los Angeles, USA), JOHN NEOPTOLEMOS (Liverpool, UK)

08:00 STATE OF THE ART LECTURE 11

ROLAND M. SCHMID (Munich, Germany): MOLECULAR BIOLOGY OF PANCREATIC CANCER.

08:25 O-30

I. Nordback, S. Rätty, J. Laukkarinen, S. Järvinen, J. Leppiniemi, M. Kellomäki, J. Sand: SIMPLE AND SAFE PANCREATICO-JEJUNOSTOMY TECHNIQUE AFTER WHIPPLE BY UTILIZING BIODEGRADABLE STENT.

08:37 O-31

V. Fendrich, P. Langer, J. Waldmann, D. Bartsch: OPERATIVE MANAGEMENT AND LONG-TERM SURVIVAL IN PATIENTS WITH NEUROENDOCRINE TUMORS OF THE PANCREAS-EXPERIENCE WITH 170 PATIENTS.

08:49 O-32

B. Forgacs, S. Heap, A. Ghazanfar, O. Mitu-Pretorian, D. Maulde, S. Mehra, B. Campbell, H. Riad, R. Pararajasingam, N. Parrott, T. Augustine, A. Tavakoli: SURGICAL CHALLENGES POST PANCREAS TRANSPLANTATION. A SINGLE CENTRE EXPERIENCE.

09:01 O-33

S. T. Barbu, I. Domsa, A. Zolog, M. Cazacu: PANCREATIC INTRAEPITHELIAL NEOPLASIA IN PANCREATA WITH AND WITHOUT DUCTAL ADENOCARCINOMA: FREQUENCY AND CLINICAL CORRELATIONS.

09:13 O-34

A. Leifler, S. Ghazi, M. Nilsson, R. Segersvärd: STANDARDIZED PATHOLOGICAL ASSESSMENT OF PANCREATIC RESECTION SPECIMENS INCREASES R1-RATE AND PROVIDES A MORE ACCURATE RECLASSIFICATION.

09:25 O-35

C. Sperti, C. Pasquali, S. Bissoli, F. Chierichetti, G. Liessi, S. Pedrazzoli: 18-FDG PET PERFORMS MUCH BETTER THAN CT IN DETECTING TUMOR RELAPSE AFTER POTENTIALLY CURATIVE PANCREATIC CANCER RESECTION AND IT MAY INFLUENCE LONG-TERM OUTCOMES.

09:37 O-36

M. Del Chiaro, C. Croce, V. G. Perrone, S. D'Imporzano, N. De Lio, D. Mariniello, N. Funel, D. Campani, F. Mosca, U. Boggi: 206 PANCREATECTOMIES PLUS RESECTION OF PERIPANCREATIC VESSELS (PRPV).

**10.00-11.40 SESSION VIII. CANCER**

Chairs: THOMAS GRESS (Marburg, Germany), GUNTER KLOPPPEL (Kiel, Germany)

10:00 STATE OF THE ART LECTURE 12

RAUL URRUTIA (Rochester, USA): PIVOTAL ROLE OF EPIGENETIC CHANGES AND MUTATIONS IN PANCREATIC CANCER.

10:25 O-37

G. Singh, S. Singh, A. König, K. Reutlinger, M. Eilers, T. Gress, M. Fernandez-Zapico, V. Ellenrieder: NFAT SWITCHES TGF- β FROM A GROWTH SUPPRESSOR TO A PROMOTER OF CELL PROLIFERATION.

10:37 O-38

M. Ohmuraya, M. Hirota, N. Ozaki, H. Baba, K. Yamamura: SERINE PROTEASE INHIBITOR, KAZAL TYPE 1 PROMOTES PROLIFERATION OF PANCREATIC CANCER CELLS THROUGH THE EPIDERMAL GROWTH FACTOR RECEPTOR.

10:49 O-39

C. W. Ang, A. Sheikh, E. Tweedle, S. Tonack, I. Schwarte-Waldhoff, P. Rooney, J. Neoptolemos, E. Costello: CROSS-TALK BETWEEN CANCER CELLS AND THEIR SURROUNDING HOST CELLS: THE ROLE OF EXOGENOUS S100A8 AND S100A9 AND THEIR RELATIONS TO TUMOURAL SMAD4 STATUS IN CARCINOGENESIS.

11:01 O-40

M. Huch, A. Gros, A. José, J. R. González, R. Alemany, C. Fillat: POTENT ANTITUMOR EFFICACY OF UPAR TRANSCRIPTIONALLY CONTROLLED ADENOVIRUSES IN MOUSE MODELS WITH PANCREATIC TUMORS AND LIVER METASTASIS.

11:13 O-41

E. Greco, A. Padoan, P. Fogar, M. Scorzeto, E. Fadi, A. Valerio, D. Bozzato, F. Navaglia, C. Zambon, C. Reggiani, S. Pedrazzoli, M. Plebani, D. Basso: THE PANCREATIC CANCER (PC) DERIVED S100A8 N-TERMINAL PEPTIDE (NT-S100A8) AUGMENTS INTRACELLULAR CA²⁺ ([CA²⁺]_i) OSCILLATIONS AND INSULIN RELEASE.

11:25 O-42

G. Lomberk, R. Urrutia: PATHWAY CROSSTALK BETWEEN KLF11 AND THE TGF- β SUPERFAMILY.

11:37 O-43

B. Kong, C.W. Michalski, H. Friess, J. Kleeff: ZINC ALPHA2-GLYCOPROTEIN IS A NOVEL TUMOR SUPPRESSOR WHICH DECREASES EPITHELIAL-TO-MESENCHYMAL TRANSDIFFERENTIATION IN PANCREATIC CANCER.

11.50-13.10 ORAL-POSTER SESSION

Chairs: ISTO NORDBACK (Tampere, Finland), VOLKER ELLENRIEDER (Marburg, Germany), MATTHIAS LOHR (Stockholm, Sweden)

11.50**OP-21**

G. Ceyhan, K. Schäfer, I. E. Demir, U. Rauch, M. Kadıhasanoglu, M. Erkan, H. Friess: NERVE GROWTH FACTOR AND ARTEMIN PROMOTE PANCREATIC NEUROPATHY IN PANCREATIC ADENOCARCINOMA.

11.54**OP-22**

C. Bertin, A. Pelletier, M. Vullierme, F. Maire, O. Henitc, V. Rebours, P. Hammel, P. Ruszniewski, P. Lévy: PANCREAS DIVISUM IS NOT A CAUSE OF PANCREATITIS BY ITSELF.

11.58**OP-23**

N. Gubergrits: PANCREATIC EXCRETORY INSUFFICIENCY AS A CAUSE OF LOW EFFICACY OF CELIAC DISEASE TREATMENT.

12.02**OP-24**

N. Shirinskaya, et al: WITHDRAWN

12.06**OP-25**

V. Klymenko, A. Klymenko: THE NEW PRINCIPLES OF SURGERY IN CHRONIC PANCREATITIS.

12.10**OP-26**

G. Lomberk, A. Mathison, M. Fernandez-Zapico, S. Ilyas, C. Demars, N. Buttar, R. Urrutia: KLF11 COMPLEXES WITH THE EPIGENETIC GENE SILENCER PROTEIN, HP1 TO MEDIATE ITS TUMOR SUPPRESSOR ACTIVITIES.

12.14**OP-27**

K. Heino, I. Nordback, J. Sand, I. Rinta-Kiikka, P. Mäntymaa, E. Koivunen, S. Rätty: SPLENIC FUNCTION AFTER LEFT PANCREATIC RESECTION.

12.18**OP-28**

P. Hammel, N. Soufir, P. Levy, V. Rebours, F. Maire, O. Hentic, P. Ruszniewski: DETECTION OF CDKN2A, CDK AND BRCA2 GENES IN PATIENTS WITH FAMILIAL PANCREATIC CANCER.

12.22**OP-29**

M. Del Chiaro, C. Moretto, C. Croce, F. Vistoli, S. D'Impozano, V. Perrone, S. Meli, U. Boggi: ROBOTIC PANCREATECTOMIES: A SINGLE INSTITUTION EXPERIENCE.

12.26**OP-30**

M. Edderkaoui, C. Nitsche, G. Eibl, A. Gukovskaya: AKT AND PKC MEDIATE NADPH OXIDASE ACTIVATION, A MAJOR PROSURVIVAL PATHWAY IN PANCREATIC CANCER CELLS, THROUGH TRANSCRIPTIONAL UP-REGULATION OF P22PHOX.

12.30**OP-31**

N. B. Jamieson, P. Glen, K. A. Oien, J. J. Going, A. K. Foulis, E. J. Dickson, C. W. Imrie, C. J. McKay, R. Carter: POSITIVE MOBILIZATION MARGINS ALONE DO NOT INFLUENCE SURVIVAL FOLLOWING PANCREATODUODENECTOMY FOR PANCREATIC DUCTAL ADENOCARCINOMA.

- 12.34 OP-32**
L. Susan, C. Serban, V. Ancusa, A. Pacurari, C. Banciu, S. Gotia, I. Romosan: RELATIONSHIP BETWEEN CIGARETTE SMOKING AND THE RISK OF PANCREATIC CANCER.
- 12.38 OP-33**
M. Parsi, R. Lopez, T. Stevens, G. Zuccaro: PREDICTORS OF A POSITIVE YIELD ON BILIARY BRUSH CYTOLOGY FOR DIAGNOSIS OF PANCREATICOBILIARY MALIGNANCY.
- 12.42 OP-34**
T. Kehl, R. Hennig, F. Bergmann, G. Fürstenberger, H. Friess, P. Krieg: RESTORATION OF 15-LIPOXYGENASE EXPRESSION IN PANCREATIC TUMOR CELLS LEADS TO GROWTH INHIBITION AND IS ASSOCIATED WITH UPREGULATION OF TUMORSUPPRESSOR P53.
- 12.46 OP-35**
N. Fox, S. Priestman, G. E. Blair, C. Verbeke: SCREENING PANCREATIC CANCERS FOR ADENOVIRUS RECEPTORS: A BASIS FOR TARGETED CANCER THERAPY.
- 12.50 OP-36**
M. Rickmann, J. M. Roig, M. Gironella, A. González, M. Guilà, X. Molero, E. C. Vaquero: DIFFERENTIAL REGULATION OF SNAIL, SLUG, ZEB1 AND MICRO-RNA200 BY TGFB AND PANCREATIC STELLATE CELLS (PSC) DURING EPITHELIAL-TOMESENCHYMAL TRANSITION (EMT) IN PANCREATIC CANCER CELLS.
- 12.54 OP-37**
E. Deerenberg, J. Poley, J. Hermans, M. Bruno, G. Kazemier, E. Kuipers, C. van Eijck: HIGH ACCURACY OF ENDOSCOPIC ULTRASONOGRAPHY (EUS) IN DIAGNOSING PATIENTS WITH SUSPECTED PANCREATIC HEAD TUMOURS AND NEGATIVE CT-SCAN.
- 12.58 OP-38**
S. Tonack, M. Aspinall-O'Dea, R. Jenkins, V. Elliott, N. Kitteringham, J. Neoptolemos, E. Costello: VALIDATION OF POTENTIAL PANCREATIC CANCER BIOMARKERS IDENTIFIED USING ITRAQ-BASED PROTEOMIC ANALYSIS OF SERUM AND PANCREATIC JUICE.
- 13.02 OP-39**
E. Rangelova, L. Strömmer, C. Ansonge, R. Segersvärd: INCREASING BMI IS POSITIVELY ASSOCIATED WITH PANCREATIC FISTULA AND COMPLICATIONS AFTER PANCREATIC RESECTIONS.
- 13.06 OP-40**
M. Chalret du Rieu, J. Torrisani, J. Selves, T. Al Saati, A. Souque, M. Dufresne, G. J. Tsongalis, A. A. Suriawinita, N. Carrère, L. Buscail, P. Cordelier: MICRORNA MIR-21 IS INDUCED EARLY IN PANCREATIC DUCTAL ADENOCARCINOMA PRECURSOR LESIONS.



**13.10-14.20 POSTER SESSION II. (SEE PAGE 51)
P092-177**

13.20-13.40 Raise or Blast Hopes: TREATMENT OF PANCREATIC CANCER
Chairs: WILLIAM GREENHALF (Liverpool, UK), LOUIS BUSCAIL (Toulouse, France)

20 min. STATE OF THE ART LECTURE 13

JOHN NEOPTOLEMOS (Liverpool, UK): PANCREATIC CANCER: PAST, PRESENT AND FUTURE.

13.40-14.25 ESPAC SATELLITE MEETING Organizer: WILLIAM GREENHALF (Liverpool, UK)

Chairs: JOHN NEOPTOLEMOS (Liverpool, UK), CLAUDIO BASSI (Verona, Italy)

JOHN NEOPTOLEMOS (Liverpool, UK): ESPAC3 RESULTS - IN CONTEXT.

CHARLOTTE RAWCLIFFE (Liverpool, UK): UPDATE ON ESPAC-4 PROGRESS.

WILLIAM GREENHALF (Liverpool, UK): ESPAC TRANSLATIONAL STUDIES.

PAULA GHANEH (Liverpool, UK), MARKUS W. BUCHLER (Heidelberg, Germany), CLAUDIO BASSI (Verona, Italy):

FUTURE ESPAC TRIALS DISCUSSION - NEOADJUVANT PROPOSALS.

14.30-16.19 SESSION IX. GENETICS

Chairs: ROLF GRAF (Zurich, Switzerland), JONAS ROSENDAHL (Leipzig, Germany)

14:30 STATE OF THE ART LECTURE 14

MIKLOS SAHIN-TOTH (Boston, USA): MECHANISMS OF GENETIC RISK IN CHRONIC PANCREATITIS.

14:55 O-44

S. Paliwal, S. Prakash, S. Bhaskar, K. R. Mani, D. N. Reddy, G. R. Chandak: COMPREHENSIVE ANALYSIS OF CTSC VARIANTS IN TROPICAL CALCIFIC PANCREATITIS IDENTIFIES NOVEL VARIANTS.

15:07 O-45

J. M. Chen, E. Masson, A. Chauvin, C. Le Maréchal, C. Férec: COPY NUMBER VARIATIONS IN CHRONIC PANCREATITIS.

15:19 O-46

M. Luaces, W. Zabala, J. Iglesias-garcia, P. Raña, A. Lozano-Leon, F. Barros, M. Castiñeira, R. Gomez-Casal, A. Carracedo, J. E. Dominguez-Munoz: MOLECULAR ANALYSIS OF SPINK1, PRSS1 AND CFTR GENES IN PATIENTS WITH CHRONIC PANCREATITIS: INFLUENCE ON SEVERITY OF THE DISEASE AT DIAGNOSIS.

15:31 O-47

V. Rebours, P. Lévy, C. Le Maréchal, P. Hammel, P. Ruzsiewicz: SYMPTOMS ARE EARLIER FROM GENERATION TO GENERATION IN PATIENTS WITH HEREDITARY PANCREATITIS.

15:43 O-48

E. Kereszturi, M. Sahin-Toth: INTRACELLULAR AUTOACTIVATION OF A HEREDITARY PANCREATITIS-ASSOCIATED CATIONIC TRYPSINOGEN MUTANT CAUSES CELL DAMAGE AND CHOP INDUCTION.

- 15:55 O-49**
P. Simon, F. Weiss, N. Bogdanova, N. Shcheynikov, S. Muallem, M. Lerch: FUNCTIONAL CHARACTERISATION OF TWO NEWLY IDENTIFIED CFTR-MUTATIONS IN IDIOPATHIC PANCREATITIS.
- 16:07 O-50**
J. Rosendahl, H. Witt, P. Kovacs, M. Stumvoll, M. Blüher, V. Keim, J. Mössner, H. Bödeker: GENETIC ANALYSIS OF (A) PAR2(TICIPATION) IN CHRONIC PANCREATITIS.



16.30-18.10 SESSION X. BASIC SCIENCE

Chairs: DAVID CRIDDLE (Liverpool, UK), ILYA GUKOVSKY (Los Angeles, USA)

- 16:30 STATE OF THE ART LECTURE 14**
ALEXEI TEPIKIN (Liverpool, UK): POLARIZED CALCIUM SIGNALING IN EXOCRINE GLAND CELLS.
- 16:55 O-51**
V. Venglovecz, P. Hegyi, Z. Rakonczay Jr., B. E. Argent, M. A. Gray: CHENODEOXYCHOLATE STIMULATES HCO₃-SECRETION IN GUINEA PIG PANCREATIC DUCTS THROUGH SELECTIVE ACTIVATION OF APICAL MAXIK+ CHANNELS.
- 17:07 O-52**
S. G. Barreto, C. Woods, C. Carati, A. Schloithe, S. P. Jaya, J. Toouli, G. Saccone: GALANIN INHIBITS CAERULEIN-STIMULATED PANCREATIC AMYLASE SECRETION FROM MOUSE PANCREATIC LOBULES VIA CHOLINERGIC NERVES AND INSULIN RELEASE.
- 17:19 O-53**
H. Y. Gee, K. H. Kim, M. G. Lee: SYNTAXIN 16 IS REQUIRED FOR THE RECYCLING OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN EPITHELIAL CELLS.
- 17:31 O-54**
P. Phillips, L. Yang, A. Poljak, S. Bustamante, A. Shulkes, A. Vonlaufen, Z. Xu, M. Guilhaus, R. Pirola, M. Apte, J. Wilson: PANCREATIC STELLATE CELLS SYNTHESISE AND SECRETE ACETYLCHOLINE: A POTENTIAL ROLE IN ENZYME SECRETION.
- 17:43 O-55**
M. Bhatia, R. Tamizhselvi: EFFECT OF HYDROGEN SULFIDE ON PI3K-AKT PATHWAY AND ON CAERULEIN-INDUCED CYTOKINE PRODUCTION IN ISOLATED MOUSE PANCREATIC ACINAR CELLS.
- 17:55 O-56**
C. Nitsche, M. Edderkaoui, J. Mayerle, M. Lerch, A. Gukovskaya: THE PHOSPHATASES PHLPP1 AND PHLPP2 DEPHOSPHORYLATE AKT KINASE THROUGH NADPH OXIDASE-DEPENDENT MECHANISM LEADING TO PANCREATIC CANCER CELL DEATH.
- 18.10-19.10 GENERAL ASSEMBLY**
- 20:30 GALA DINNER (HOTEL TISZA CONCERT AND MIRRORS HALL)**
Address: Szeged, Széchenyi tér 3

Scientific Programme

Saturday,

4th July, 2009

POSTGRADUATE
COURSE AND
BASIC SCIENCE
SATELLITE
DAY4

07.30-12:00 REGISTRATION

08.00-08.05 OPENING OF THE MEETING

08.05-08.20 PRE-MEETING TEST

08.30-10.05 SATELLITE I. PANCREATIC ACINI 1

Chairs: ASHOK SALUJA (Minneapolis, USA), ALEXEI TEPIKIN (Liverpool, UK)

08:30 SATELLITE LECTURE 1
ANDRAS SPAT (Budapest, Hungary): GENERAL ASPECTS OF MITOCHONDRIAL FUNCTION.

08:50 SATELLITE LECTURE 2
OLE PETERSEN (Liverpool, UK): BIONERGETICS OF PANCREATIC ACINAR CELLS.

09:10 SATELLITE LECTURE 3
PETER THORN (Brisbane, Australia): EXOCYTOTIC MECHANISMS IN THE PANCREATIC ACINAR CELLS.

09:30 SATELLITE LECTURE 4
ANTONY GALIONE (Oxford, UK): ROLE OF NAADP MEDIATED CALCIUM SIGNALING IN PANCREATIC ACINAR CELLS.

09:50 SUMMARY AND DISCUSSION MODERATED BY
ALEXEI TEPIKIN (Liverpool, UK)



10.25-12.00 SATELLITE II. PANCREATIC ACINI 2

Chairs: STEPHEN PANDOL (Los Angeles, USA), JEAN MORISSET (Sherbrooke, Canada)

10:25 SATELLITE LECTURE 5
JULIA GERASIMENKO (Liverpool, UK): PANCREATIC PROTEASE ACTIVATION BY ALCOHOL METABOLITE DEPENDS ON CA₂⁺ RELEASE VIA ACID STORE IP₃ RECEPTORS

10:45 SATELLITE LECTURE 6
ANNA GUKOVSKAYA (Los Angeles, USA): AUTOPHAGY IN PANCREATITIS.

11:05 **SATELLITE LECTURE 7**
JULIA MAYERLE (Greifswald, Germany): UPDATE IN THE INFLAMMATORY RESPONSES IN ACUTE PANCREATITIS.

11:25 **SATELLITE LECTURE 8**
LEENA ALHONEN (Kuopio, Finland): THE ROLE OF POLYAMINES IN PANCREATITIS.

11:45 **SUMMARY AND DISCUSSION MODERATED BY**
JEAN MORISSET (Sherbrooke, Canada)

13.00-14.35 **SATELLITE III. GENETIC BASIS OF PANCREATITIS**
Chairs: CLAUDE FEREC (CHU de Brest, France), MIKLOS SAHIN-TOTH (Boston, USA)

13:00 **SATELLITE LECTURE 9**
DAVID C. WHITCOMB (Pittsburg, USA): PANCREATIC GENETICS TODAY AND TOMORROW.

13:20 **SATELLITE LECTURE 10**
HEIKO WITT (Munich, Germany): NOVEL GENETIC RISK FACTORS IN PANCREATITIS.

13:40 **SATELLITE LECTURE 11**
MILAN MACEK JR. (Prague, Czech Republic): ROLE OF CFTR GENE (CYSTIC FIBROSIS) MUTATIONS AND VARIANTS.

14:00 **SATELLITE LECTURE 12**
GIRIRAJ R. CHANDAK (Hyderabad, India): GENETICS OF TROPICAL PANCREATITIS IN INDIA.

14:20 **SUMMARY AND DISCUSSION MODERATED BY**
CLAUDE FEREC (CHU de Brest, France)



14.50-16.05 **SATELLITE IV. PANCREATIC DUCTS 1**
Chairs: MANOOCHER SOLEIMANI (Cincinnati, USA), ZOLTAN RAKONCZAY (Szeged, Hungary)

14:50 **SATELLITE LECTURE 13**
JOSÉ I. SAN ROMAN (Salamanca, Spain): PHYSIOLOGY OF PANCREATIC DUCTAL BICARBONATE SECRETION.

15:10 **SATELLITE LECTURE 14**
SHMUEL MUALLEM (Dallas, USA): CONTRAVERSIES IN THE ROLE OF SLC26 ANION EXCHANGERS IN PANCREATIC DUCTAL BICARBONATE SECRETION.

15:30 **SATELLITE LECTURE 15**
HIROSHI ISHIGURO (Nagoya, Japan): INTERACTION BETWEEN CFTR CL⁻ CHANNEL AND SLC26 ANION EXCHANGERS.

15:50 **SUMMARY AND DISCUSSION MODERATED BY**
MANOOCHER SOLEIMANI (Cincinnati, USA)



16.25-18.00 **SATELLITE V. PANCREATIC DUCTS 2**
Chairs: SHMUEL MUALLEM (Dallas, USA), GABOR VARGA (Budapest, Hungary)

16:25 **SATELLITE LECTURE 17**
DAVID N. SHEPPARD (Bristol, UK): STRUCTURE AND FUNCTION OF THE CFTR CHLORIDE CHANNEL.

16:45 **SATELLITE LECTURE 16**
MIN GOO LEE (Seoul, Korea): CHLORIDE DEPENDENT BICARBONATE TRANSPORT BY CFTR.

17:05 **SATELLITE LECTURE 18**
MIKE GRAY (Newcastle, UK): THE EFFECT OF BILE ACIDS ON ION CONDUCTANCES IN PANCREATIC DUCT CELLS.

17:25 **SATELLITE LECTURE 19**
VIKTORIA VENGLOVECZ (Szeged, Hungary): THE ROLE OF PANCREATIC DUCTS IN ACUTE PANCREATITIS.

17:45 **SUMMARY AND DISCUSSION MODERATED BY**
SHMUEL MUALLEM (Dallas, USA)

18.00-18.15 **POST-MEETING TEST**

19:00 **SOCIAL PROGRAM (BUFFET DINNER AND WELLNESS AT ANNA BATH)**
Address: Szeged, Tisza Lajos krt. 24

21:00 **OPTIONAL SOCIAL PROGRAM (OPEN-AIR THEATRE)**
Address: Szeged, Dom tér

Scientific Programme

Saturday,

4th July, 2009

POSTGRADUATE
COURSE AND
CLINICAL SCIENCE
SATELLITE
DAY4

07.30-12:00 **REGISTRATION**

09.00-09.05 **OPENING THE MEETING**

09.05-09.20 **PRE-MEETING TEST**

09.20-10.40 **SATELLITE I. ENDOSCOPY**

Chairs: AKOS PAP (Budapest, Hungary), DANIEL BLERO (Brussels, Belgium)

09:20 **SATELLITE LECTURE 1**

AKOS PAP (Budapest, Hungary): DIAGNOSTIC AND OPERATIVE ENDOSCOPY IN PANCREATIC CANCER.

09:40 **SATELLITE LECTURE 2**

DANIEL BLERO (Brussels, Belgium): ENDOSCOPIC TREATMENT OF CHRONIC PANCREATITIS.

10:00 **SATELLITE LECTURE 3**

PETR DITE (Prague, Czech Republic): ENDOSCOPIC TREATMENT OF THE BILIARY TRACT IN PANCREATIC DISEASES.

10:20 **SATELLITE LECTURE 4**

COLIN MCKAY (Glasgow, Scotland): ENDOSCOPY IN ACUTE PANCREATITIS.



11.00-12.00 **SATELLITE II. ENTERAL FEEDING AND NUTRITION**

Chairs: TAMAS TAKACS (Szeged, Hungary), CLEM IMRIE (Glasgow, Scotland)

11:00 **SATELLITE LECTURE 5**

VAY LIANG W. (BILL) GO (Los Angeles, USA): NUTRITION IN PANCREATIC DISEASES.

11:20 **SATELLITE LECTURE 6**

CHRISTOPH BEGLINGER (Basel, Switzerland): PANCREATIC DISEASE AND METABOLIC DISORDERS.

11:40 **SATELLITE LECTURE 7**

STEPHEN J. O'KEEFE (Pittsburgh, USA): ENTERAL FEEDING IN ACUTE PANCREATITIS.



13.00-14.20 **SATELLITE III. SURGERY**

Chairs: ATTILA OLAH (Gyor, Hungary), CLAUDIO BASSI (Verona, Italy)

13:00 **SATELLITE LECTURE 8**

HELMUT FRIESS (Munich, Germany): SURGERY OF CHRONIC PANCREATITIS.

13:20 **SATELLITE LECTURE 9**

AKE ANDREN-SANDBERG (Stockholm, Sweden): NEW HORIZONS IN PANCREATIC CANCER.

13:40 **SATELLITE LECTURE 10**

CLAUDIO BASSI (Verona, Italy): ROLE OF SURGERY IN ACUTE PANCREATITIS.

14:00 **SATELLITE LECTURER 11**

RICHARD CHARNLEY (Newcastle, UK): MINIMAL INVASIVE TECHNIQUES IN PANCREATIC SURGERY.



14.40-15.45 **SATELLITE IV. GUIDELINES**

Chairs: ALEXANDER SCHNEIDER (Mannheim, Germany), CHRISTOPH Dervenis (Athens, Greece)

14:40 **SATELLITE LECTURER 12**

CHRISTOPH Dervenis (Athens, Greece): GUIDELINES IN ACUTE PANCREATITIS.

15:05 **SATELLITE LECTURER 13**

JOACHIM MOSSNER (Leipzig, Germany): GUIDELINES FOR CHRONIC PANCREATITIS.

15:25 **SATELLITE LECTURER 14**

THOMAS SEUFFERLEIN (Halle, Germany): TREATMENT OF PANCREATIC CANCER.

15.45-16.00 **POST-MEETING TEST**

19:00 **SOCIAL PROGRAM (BUFFET DINNER AND WELLNESS AT ANNA BATH)**

Address: Szeged, Tisza Lajos krt. 24

21:00 **OPTIONAL SOCIAL PROGRAM (OPEN-AIR THEATRE)**

Address: Szeged, Dóm tér

POSTER SESSION I. P001-091

BASIC SCIENCE – ACUTE PANCREATITIS P001-P023

Chairs: MARIA VACCARO (Buenos Aires, Argentina), DANIELA BASSO (Padova, Italy)

P-001

S. Yubero, L. Ramudo, M. A. Manso, J. Sanchez-Recio, E. Weruaga, I. De Dios: DEXAMETHASONE DOWN-REGULATED ICAM-1 IN NECROTIZING ACUTE PANCREATITIS BUT FAILED TO PREVENT LEUKOCYTE RECRUITMENT.

P-002

G. Biczó, P. Hegyi, S. Berczi, B. Iványi, Z. Hracsko, I. S. Varga, T. Takacs, Z. Rakonczay Jr: ARGINASE INHIBITION REDUCES PANCREATIC DAMAGE IN L-ARGININE-INDUCED ACUTE PANCREATITIS IN RATS.

P-003

I. De Dios, S. Yubero, L. Ramudo, S. Vicente, M. A. Manso: EFFECT OF DEXAMETHASONE ON CHEMOKINE EXPRESSION DURING BILE-PANCREATIC DUCT OBSTRUCTION-INDUCED ACUTE PANCREATITIS.

P-004

I. Demeter, O. Hegyesi, A. Nagy, R. M. Case, M. C. Steward, G. Varga, B. Burghardt: TRANSEPITHELIAL HCO_3^- TRANSPORT IN HPAF PANCREATIC DUCT CELL LINE.

P-005

M. Ellis, J. French, R. Charnley: RISK FACTORS FOR EARLY MORTALITY IN ACUTE PANCREATITIS.

P-006

J. Escobar, J. Pereda, A. Arduini, J. Sandova, N. Sacilotto, L. Sabater, L. Aparisi, G. López-Rodas, J. Sastre: ROLE OF SER/THR PHOSPHATASE PP2A IN ACUTE PANCREATITIS: THE MECHANISM BEHIND PENTOXIFYLLINE TREATMENT.

P-007

S. Galeev, M. Rubtsov, O. Klitsenko: EARLY SURGERY IN ACUTE NON-BILIARY PANCREATITIS.

P-008

S. Gea-Sorli, D. Closa: REVERSIBILITY OF PERITONEAL MACROPHAGES ACTIVATION DURING EXPERIMENTAL ACUTE PANCREATITIS.

P-009

A. Gulbinas, E. Jansen, Z. Dambrauskas, G. Barauskas: OXIDATIVE STRESS MARKERS IN ACUTE PANCREATITIS PATIENTS.

P-010

W. Huang, R. Mukherjee, D. Booth, A. Tepikin, O. Petersen, D. Criddle, R. Sutton: CAFFEINE AMELIORATES MURINE CAERULEIN-INDUCED ACUTE PANCREATITIS.

P-011

J. Jaworek, J. Szklarczyk, K. Nawrot-Porabka, M. Kot, K. Zwirska-Korczała, M. Szczepanik, S. J. Konturek, W. W. Pawlik: PINEALECTOMY MODULATES CD4/CD8 LYMPHOCYTE RATIO AND CYTOKINE PRODUCTION IN THE RATS WITH ACUTE PANCREATITIS (AP).

Chairs: JOLANTA JAWOREK (Krakow, Poland), MARLÉNE DUFRESNE (Toulouse, France)

P-012

J. Mehta, R. Prabhu: CAN CA 19-9 AND CEA PREDICT PANCREATIC MALIGNANCIES.

P-013

C. Nitsche, R. Moore, J. Mayerle, M. Lerch, A. Gukovskaya: GROWTH FACTOR WITHDRAWAL STIMULATES AUTOPHAGY AND APOPTOSIS THROUGH AKT INHIBITION.

P-014

P. Pallagi, Z. Rakonczay Jr, T. Takacs, V. Venglovecz, J. Lonovics, T. Wittmann, K. Borka, B. Ózsvari, M. Sahin-Toth, P. Hegyi: TRYPSIN INHIBITS A CHLORIDE INDEPENDENT PANCREATIC DUCTAL BICARBONATE SECRETION VIA PROTEASE-ACTIVATED RECEPTOR 2.

P-015

A. Kazyulin, I. Koroleva, J. Kucheryavyi, M. Byahov: PANCREATIC TOXICITY DURING AND AFTER NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER.

P-016

O. Krylova: THERAPEUTIC EFFECTS OF PANCREOFIL IN EXPERIMENTAL CHRONIC PANCREATITIS AND DIABETES MELLITUS.

P-017

D. Janjic, V. Petrovic, M. Stojanovic, S. Mihajlovic, M. Nestorovic: ERCP AND EPT IN ACUTE COMPLICATED PANCREATITIS: A CASE REPORT.

P-018

A. Szejarto, C. Fulop, Z. Fazekas, T. Verebely, L. Harsanyi: DIAGNOSTIC DIFFICULTIES AND TREATMENT OF PANCREATIC TUMORS IN CHILDHOOD: REPORT OF TWO CASES.

P-019

A. Uimari, M. Merentie, T. Fashe, L. Alhonen: ZN-INDUCED ACUTE PANCREATITIS IN THE MICE WITH MODIFIED POLYAMINE METABOLISM.

P-020

B. Knight, D. Sherlock, M. Manu, D. O'Reilly: OUTCOME PREDICTORS AFTER MAJOR PANCREATIC SURGERY; THE ROLE OF POSSUM, P-POSSUM AND THE GLASGOW PROGNOSTIC SCORE.

P-021

J. Laukkarinen, G. Perides, M. Steer: NON-DETERGENT MEDIATED BILE SALT (TAUROLITHOCHOLIC ACID 3-SULFATE, TLCS) - INDUCED ACUTE PANCREATITIS.



P-022

S. Trapp, J. Mayerle, A. Dummer, M. Sendler, F. U. Weiss, W. Halangck, M. M. Lerch: **THE GREATER SEVERITY OF PANCREATITIS IN CFTR MUTATED MICE IS INDEPENDENT OF ACINAR CELL EFFECTS.**

P-023

Z. Warzecha, P. Ceranowicz, M. Dembinski, J. Cieszkowski, B. Kusniercz-Cabala, R. Tomaszewska, A. Dembinski: **HEALING EFFECT OF HEPARIN IN THE COURSE OF EDEMATOUS, CERULEIN-INDUCED ACUTE PANCREATITIS.**

BASIC SCIENCE – CHRONIC PANCREATITIS P024-P027

Chairs: YASUYUKI KIHARA (Kitakyushu, Japan), RICHARD SZMOLA (Boston, USA)

P-024

S. R. Gotia, L. Susan, O. Chirileanu, L. S. Gotia: **CHRONIC PANCREATITIS AND ALCOHOL ABUSE.**

P-025

M. Guilà, A. M. González, M. Rickmann, E. C. Vaquero, X. Molero: **THE COX-2 INHIBITOR CELECOXIB INDUCES PROGRAMMED CELL DEATH IN RAT PANCREATIC STELLATE CELLS.**

P-026

L. Lazebnik, L. Vinokurova, I. Trubitsina, E. Tkachenko, G. Varvanina, A. Gubina: **THE ROLE OF NEUROHORMONAL REGULATION IN ADAPTATION MECHANISMS IN PATIENTS WITH CHRONIC PANCREATITIS.**

P-027

Y. Shimokawa, T. Oono, T. Nakamura, N. Fujimori, H. Igarashi, M. Yasuda, Y. Niina, M. Uchida, T. Ito: **ROLE OF FIBROGENIC AND TH1/TH2 CYTOKINES IN EARLY PANCREATIC FIBROGENESIS.**

BASIC SCIENCE – PANCREATIC CANCER P028-P054

Chairs: MADHAV BHATIA (Singapore, Singapore), Marco Del Chiaro (Pisa, Italy)

P-028

A. Aghdassi, F. U. Weiss, C. O. Behn, J. Mayerle, M. W. Büchler, H. Friess, C. D. Heidecke, M. M. Lerch: **ZEB1 ASSOCIATES WITH THE E-CADHERIN PROMOTER AND INHIBITS E-CADHERIN EXPRESSION VIA RECRUITMENT OF HDAC1 AND HDAC2 IN PANCREATIC CANCER.**

P-029

M. Aspinall-O'Dea, S. Tonack, R. Jenkins, V. Elliott, N. Kitteringham, J. Neoptolemos, E. Costello: **CHARACTERISATION OF ABUNDANT PROTEINS IN THE PANCREATIC CANCER SERUM PROTEOME AND THEIR ASSOCIATED MARKERS.**

P-030

K. Dajani, S. Tonack, W. Greenhalf, J. Neoptolemos, E. Costello, P. Ghaneh: **GEMCITABINE RESISTANCE CORRELATES WITH THE EXPRESSION OF KEY PROTEINS IN ITS UPTAKE AND METABOLISM IN PANCREATIC CANCER CELL LINES.**

P-031

A. Dauksa, O. El-Maarri, G. Barauskas, Z. Dambrasukas, A. Gulbinas, J. Oldenburg: **GLOBAL AND PROMOTER METHYLATION IN PERIPHERAL BLOOD OF PANCREATIC CANCER PATIENTS.**

P-032

B. Diergaarde, R. Brand, J. Lamb, S. Y. Cheong, K. Stello, M. M. Barmada, E. Feingold, D. C. Whitcomb: **GENOME-WIDE ASSOCIATION STUDY IMPLICATES GAMMA-GLUTAMYLTRANSFERASE 1 (GGT1) GENE IN PANCREATIC CARCINOGENESIS.**

P-033

P. Fogar, E. Fadi, E. Greco, G. Pantano, A. Padoan, D. Bozzato, M. Facco, M. Sanzari, S. Teolato, G. Semenzato, S. Pedrazzoli, M. Plebani, D. Basso: **PANCREATIC CANCER (PC) ALTERS HUMAN CD4+ T LYMPHOCYTE FUNCTION: A PIECE OF THE IMMUNEVIASION PUZZLE.**

Chairs: FRANK ULRICH WEISS (Greifswald, Germany), CRISTINA FILLAT (Barcelona, Spain)

P-034

P. Fogar, F. Navaglia, L. Moserle, C. Zambon, A. Padoan, E. Greco, E. Fadi, S. Moz, D. Bozzato, S. Indraccolo, S. Pedrazzoli, A. Parenti, M. Plebani, D. Basso: **PANCREATIC CANCER (PC) GENE THERAPY WITH HEAT INDUCIBLE DIPHTHERIA TOXIN VARIANT CRM197 (DTA197): IN VIVO PRELIMINARY RESULTS.**

P-035

N. Funel, L. E. Pollina, U. Boggi, M. Del Chiaro, F. Mosca, D. Campani: **TRANSFECTION OF SIRNA FOR ERK1-2 IN PRIMARY PANCREATIC CANCER CELLS CULTURES BY ELECTROPORATION REDUCE THE CELL GROWTH IN VITRO.**

P-036

N. Funel, E. Giovannetti, W. Nowicky, L. E. Pollina, M. Del Chiaro, G. J. Peters, F. Mosca, U. Boggi, D. Campani: **SELECTIVE EFFECT OF UKRAIN IN PRIMARY PANCREATIC TUMOR CELL CULTURES.**

P-037

N. Funel, W. Nowicky, L. E. Pollina, M. Baron, M. Del Chiaro, E. Giovannetti, G. J. Peters, F. Mosca, U. Boggi, D. Campani: **HOMOZYGOSIS MUTATION IN K-RAS ONCOGENE IN PRIMARY CELL CULTURE FROM PANCREATIC DUCTAL ADENOCARCINOMA. CHARACTERISTIC OF THE TUMOR OR ADAPTATION IN VITRO?**

P-038

N. Funel, S. Pelliccioni, M. Del Chiaro, L. E. Pollina, A. Michelucci, P. Sirmi, F. Mosca, U. Boggi, D. Campani: **PMP22 GENE DUPLICATION IN PANCREATIC DUCTAL ADENOCARCINOMA.**

P-039

M. Hermanova, P. Karasek, R. Nenutil, M. Kyr, J. Tomasek, I. Baltasova, P. Dite: **CLINICOPATHOLOGICAL CORRELATIONS OF CYCLOOXYGENASE-2, MDM2, AND P53 EXPRESSIONS IN SURGICALLY RESECTABLE PANCREATIC INVASIVE DUCTAL ADENOCARCINOMA.**

Chairs: KAZUICHI OKAZAKI (Hirakata, Japan), GWEN LOMBERK (Los Angeles, USA)

P-040

X. Jia, J. Larsson, F. Wang, J. Permert: GLYCOLYSIS IN PANCREATIC CANCER CELLS IS A DRIVING FORCE FOR SKELETAL MUSCLE WASTING IN CANCER-ASSOCIATED CACHEXIA.

P-041

A. Leja-Szpak, J. Jaworek, P. Pierzchalski, W. W. Pawlik: MELATONIN INDUCES PROAPOPTOTIC SIGNALING PATHWAY IN HUMAN PANCREATIC CARCINOMA CELLS (PANC-1): INVOLVEMENT OF BAX AND CASPASE 9.

P-042

N. B. Jamieson, J. P. Morton, O. J. Sansom, E. J. Dickson, R. Carter, K. A. Oien, C. J. McKay: THE TUMOUR SUPPRESSOR GENE LKB1 IS ASSOCIATED WITH PROGNOSIS IN PANCREATIC DUCTAL ADENOCARCINOMA.

P-043

A. Nikolic, J. Dinic, S. Lukic, V. Djordjevic, D. Popovic, D. Radjkovic: ANGIOTENSIN-CONVERTING ENZYME INSERTION/DELETION POLYMORPHISM IN PATIENTS WITH PANCREATIC CANCER AND CHRONIC PANCREATITIS.

P-044

S. Murray, S. Tonack, M. Aspinall-O'Dea, R. Jenkins, V. Elliot, C. Lane, J. Neoptolemos, E. Costello: SEARCHING FOR EARLY STAGE PANCREATIC CANCER BIOMARKERS USING ITRAQ.

P-045

T. Nedjadi, C. Ang, A. Sheikh, J. Neoptolemos, E. Costello: CHARACTERISATION OF CYTOKINE-MEDIATED CROSSTALK BETWEEN PANCREATIC CANCER AND MONOCYTIC CELLS.

P-046

M. N. Orizu, C. Williams, S. Murray, J. Neoptolemos, W. Greenhalf: DEVELOPMENT OF A COMBINATION SCREEN FOR PANCREATIC CANCER INVOLVING DETECTION OF CIRCULATING TUMOUR CELLS AND K-RAS MUTATIONS IN THE PLASMA.

Chairs: GÜRALP CEYHAN (Munich, Germany), DANIELA CAMPANI (Pisa, Italy)

P-047

P. Phillips, L. Yang, A. Vonlaufen, Z. Xu, A. Biankin, D. Goldstein, R. Pirola, J. Wilson, M. Apte: HEAT SHOCK PROTEINS ARE INDUCED DURING PANCREATIC STELLATE CELL ACTIVATION IN PANCREATIC CANCER.

P-048

P. Phillips, E. Chow, W. Kaplan, M. Cowley, A. Vonlaufen, L. Yang, Z. Xu, A. Biankin, D. Goldstein, R. Pirola, J. Wilson, M. Apte: GENE EXPRESSION PROFILING OF HUMAN PANCREATIC STELLATE CELLS AND THEIR ROLES IN PANCREATIC CANCER PROGRESSION.

P-049

E. Pomianowska, I. P. Gladhaug IP, K. Grzyb, B. R. Røsk, B. Edwin, D. Bergestuen, Ø. Mathisen: PREDICTORS OF SURVIVAL AFTER SURGICALLY RESECTED PANCREATIC ENDOCRINE TUMOURS: IMPORTANCE OF WHO CLASSIFICATION, R- STATUS AND KI-67 EVALUATION.

P-050

A. A. Sheikh, C. W. Ang, S. Tonack, T. Nedjadi, A. Dodson, F. Campbell, J. Neoptolemos, E. Costello: THE CORRELATION OF TGF-BETA EXPRESSION IN PANCREATIC CANCER AND S100A8/S100A9 EXPRESSION OF STROMAL MONOCYTES.

P-051

K. Sjöberg, M. Johansson, A. Hyltander, E. Kalaitzakis, M. Shafazand, J. Hansen, H. Sjøvall, G. Hansson, R. Sadik: PROTEOMIC ANALYSIS OF CYST FLUID MUCIN EXPRESSION IS USEFUL IN THE CLINICAL ASSESSMENT OF PANCREATIC CYSTIC LESIONS.

P-052

C. Tanase, L. Albulescu, S. Dima, T. Dumitrascu, S. Mihaj, D. Popescu, E. Raducan, M. Poroschianu, A. Ionita, R. Albulescu, I. Popescu: SERUM CYTOKINE PROFILES IN PANCREATIC CANCERS.

P-053

F. Wang, J. Larsson, M. Herrington, J. Permert: PP56 IMPROVES ENERGY HOMEOSTASIS IN A MOUSE MODEL OF PANCREATIC CANCER.

P-054

I. Abiatari, B. Kong, H. Friess, J. Kleeff: HSULF1 REGULATES EXPRESSION AND FUNCTIONAL ACTIVITY OF HIP/RPL29 IN PANCREATIC CANCER.

BASIC SCIENCE – PHYSIOLOGY P055-P060

Chairs: THOMAS GRIESBACHER (Graz, Austria), MIKE GRAY (Newcastle upon Tyne, UK)

P-055

D. Masulovic, A. Djuric-Stefanovic, D. Saranovic, A. Ivanovic: CT PRESENTATION OF NORMAL PANCREAS: COMPARISON BETWEEN SPIRAL AND MDCT.

P-056

I. Trubitsina, B. Chikunova, L. Vinokurova: SEROTONIN IN THE RATS WITH EXPERIMENTAL ACUTE AND CHRONIC PANCREATITIS.

P-057

H. W. Park, J. H. Nam, K. H. Kim, M. G. Lee: CHLORIDE-DEPENDENT BICARBONATE TRANSPORT BY CFTR.

P-058

K. Nawrot-Porabka, J. Jaworek, A. Leja-Szpak, M. Kot, W. W. Pawlik, S. Lange, B. Sterby: EFFECT OF ANTISECRETORY FACTOR (AF) ON AMYLASE RELEASE FROM PANCREATIC ACINI AND ON PANCREATIC CCK-A RECEPTOR.

P-059

H. W. Park, M. G. Lee: REGULATION OF SLC26 TRANSPORTERS BY THE STE20P KINASES.

P-060

L. Selig, G. Klöppel, H. Wittenburg, R. Gebhardt, V. Keim, J. Mössner, H. Bödeker: INFLUENCE OF AGE ON THE PHENOTYPE OF R122H_HPRSS1-TRANSGENIC BALB/C MICE.

CLINICAL SCIENCE – ACUTE PANCREATITIS P061-P091

Chairs: LJILJANA PETRONJEVIC (Belgrade, Serbia), DAVOR STIMAC (Rijeka, Croatia)

P-061

I. Bihalsky, S. Chooklin: ENCEPHALOPATHY IN ACUTE PANCREATITIS: PATHOGENESIS AND TREATMENT.

P-062

S. Chooklin, O. Hranat: SPLEEN LESIONS IN ACUTE PANCREATITIS.

P-063

N. Chooklina, S. Chooklin: HYPERTRIGLYCERIDEMIA-INDUCED ACUTE PANCREATITIS IN PREGNANCY.

P-064

D. Radenkovic, D. Bajec, N. Ivancevic, P. Gregoric, A. Karamarkovi, V. Djukic, Z. Lausevic, S. Krstic, D. Mirkovic, B. Karadzic, V. Cijan, D. Bilanovic, D. Radovanovic, B. Stefanovic, V. Jeremic: DECOMPRESSIVE LAPAROTOMY WITH TEMPORARY ABDOMINAL CLOSURE VERSUS PERCUTANEOUS PUNCTURE WITH PLACEMENT OF ABDOMINAL CATHETER IN PATIENTS WITH ABDOMINAL COMPARTMENT SYNDROME DURING ACUTE PANCREATITIS (DECOMPRESS STUDY): BACKGROUND AND DESIGN OF MULTICENTER, RANDOMISED, CONTROLLED STUDY.

P-065

M. Dal Molin, G. Butturini, S. Partelli, R. Salvia, L. Casetti, GC. Mansueto, C. Bassi, P. Pederzoli: THE CLINICAL MANAGEMENT AND OUTCOME OF HEMORRHAGE AFTER PANCREATODUODENECTOMY: RESULTS IN A CONTINUOUS SERIES OF 755 PATIENTS.

P-066

P. Gregoric, D. Bajec, D. Radenkovic, N. Ivancevic, V. Jeremic, B. Karadzic, D. Milivojevic, B. Bojicic: ROLE OF D-DIMER IN PREDICTION OF ORGAN FAILURE IN ACUTE PANCREATITIS.

P-067

O. Hranat, S. Chooklin, M. Lyba: ACUTE PANCREATITIS: ROLE OF CYCLOOXYGENASE-2 AND ENDOTHELIN-1.

P-068

J. Khan, T. Solakivi, H. Pelli, R. Lappalainen-Lehto, S. Järvinen, S. T. Nikkari, J. Sand, I. Nordback: SERUM FATTY ACID PROFILES IN ALCOHOL INDUCED ACUTE PANCREATITIS.

P-069

D. Khokha, V. Khokha, A. Litvin: MANAGEMENT OF PATIENTS WITH ACUTE PANCREATITIS: ROLE OF MINIMAL ACCESS TECHNIQUES.

Chairs: DEJAN RADENKOVIC (Belgrade, Serbia), MASARU KOIZUMI (Tsukidate, Japan)

P-070

Y. Kihara, M. Otsuki, M. Harada: EFFECTIVENESS OF APPROPRIATE FLUID RESUSCITATION IN SEVERE ACUTE PANCREATITIS.

P-071

P. G. Lankisch, B. Weber-Dany, P. Maisonneuve, A. B. Lowenfels: RAISED SERUM CREATININE: MARKER FOR PANCREATIC NECROSIS IN ACUTE PANCREATITIS? RESULTS OF A PROSPECTIVE MULTICENTRE STUDY.

P-072

J. Laukkarinen, J. Sand, V. Autio, I. Nordback: DIAGNOSED HYPOTHYROIDISM IS A RISK FACTOR FOR COMMON BILE DUCT STONES.

P-073

B. Lesniowski, A. Kumor, P. Daniel, M. Pietruczuk, E. Malecka-Panas: IL-18, GHRELIN, AND ACUTE INFLAMMATORY PHASE FACTORS CONCENTRATION IN SERUM IN PATIENTS WITH ACUTE PANCREATITIS (AP).

P-074

B. Lindkvist, S. Appelros, S. Regner, J. Manjer: MODERATELY ELEVATED SERUM TRIGLYCERIDE LEVELS ARE ASSOCIATED WITH AN INCREASED RISK FOR ACUTE PANCREATITIS. REPORT FROM A PROSPECTIVE COHORT STUDY.

P-075

A. Litvin, V. Khokha: THE EARLY PREDICTION OF INFECTED PANCREATIC NECROSIS.



P-076

P. Kongsuphol, F. Romeiras, D. Cassidy, R. Schreiber, A. Mehta, K. Kunzelmann: MOLECULAR MODELLING LINKING ACIDOSIS TO PANCREATITIS IN PATIENTS BEARING THE CFTRMUTATION S573C: IS METFORMIN A FACTOR?

P-077

J. Panek, M. Dolecki, H. Plutecka, J. Bonior, Z. Biesiada: THE CONCENTRATION OF LEUKOTRIENE E4 IN THE URINE OF PATIENTS WITH MILD AND SEVERE ACUTE PANCREATITIS.

Chairs: JAN TRNA (Brno, Czech Republic), XAVIER MOLERO (Barcelona, Spain)

P-078

A. Pap, M. Burai, A. Tarpay: NOVEL TREATMENT FOR WALLED-OFF NECROSIS (WON).

P-079

Perejaslov A: IMPLICATION OF IL-17 IN HEMATOLOGICAL CHANGES IN ACUTE PANCREATITIS.

P-080

Albokrinov A., A. Perejaslov: ENTERAL NUTRITION ATTENUATES THE INFLAMMATORY RESPONSE SYNDROME IN CHILDREN WITH SEVERE PANCREATITIS.

P-081

I. Korinevska, A. Perejaslov, A. Dvorakevych: LAPAROSCOPY IN THE DIAGNOSTIC AND MANAGEMENT OF PANCREATIC TRAUMA IN CHILDREN.

P-082

G. Piccinni, A. Sciusco, E. Poli, D. Petrozza, D. Lardo, A. Gurrado, M. Testini: MANAGING MILD ACUTE BILIARY PANCREATITIS: OUR PROTOCOL.

P-083

I. Krznaric-Zrnica, L. Bilic-Zulle, E. Fistic, S. Milic, J. Stanac: SEVERITY OF ACUTE PANCREATITIS – IS THERE A RELATIONSHIP WITH AGE?

P-084

G. Poropat, I. Spanjol-Pandelo, V. Licul, I. Krznaric-Zrnica, D. Stimac: THE INFLUENCE OF BMI, WAIST AND HIP CIRCUMFERENCE ON THE SEVERITY OF ACUTE PANCREATITIS.

Chairs: DAVID FINE (Southampton, UK), JOACHIM MOSSNER (Leipzig, Germany)

P-085

A. Rosztoczy, F. Izbeki, R. Roka, K. Gecse, T. Takacs, J. Janosi, T. Wittmann: FASTING TYPE GASTROINTESTINAL MOTILITY RETURNS AND REPLACES DIGESTIVE TYPE MOTILITY DURING CONTINUOUS ENTERAL FEEDING (CEF) IN PATIENTS WITH PANCREATITIS AND PANCREATIC PSEUDOCYST.

P-086

E. Schafer, K. Ruzsnyak, Z. Visnyei, F. Zsigmond, I. Arva, T. Karner, A. Bursics, T. Gyokeres, J. Banai: THE ROLE OF THE COAGULATION SYSTEM IN PREDICTING MULTIORGAN FAILURE IN ACUTE PANCREATITIS – A PILOT STUDY IN OUR DEPARTMENT.

P-087

L. Susan, C. Serban, V. Ancusa, C. Banciu, A. Pacurari, S. Gotia, I. Romosan: THE ROLE OF ABDOMINAL ULTRASONOGRAPHY IN DIAGNOSIS OF PANCREATIC DISEASES.

P-088

I. Kovalska, T. Lubenets: PATHOMORPHOLOGICAL CHANGES AND PERSPECTIVES OF SEVERE ACUTE PANCREATITIS.

P-089

V. Boiko, O. Pesotsky, A. Kozachenko, V. Ivanov, A. Vasko: MINIMIZATION OF OPERATIONAL TRAUMA AS A WAY TO IMPROVE THE RESULTS OF TREATMENT IN PATIENTS WITH DESTRUCTIVE PANCREATITIS.

P-90

Z. Visnyei, E. Schafer, K. Ruzsnyak, A. Ivanyi, G. Varga, A. Bursics, I. Arva, T. Karner, J. Sandor, T. Gyokeres, J. Banai: DOES HYPERLIPIDAEMIA, OBESITY AND EARLY HYPERGLYCAEMIA CONFER AN INCREASED RISK AND/OR MORE SEVERE COURSE OF ACUTE PANCREATITIS? RETROSPECTIVE ANALYSIS IN OUR DEPARTMENT.

P-91

J. P. Arancibia, C. Mancilla, P. Palavecino, Z. Berger: INTRA-ABDOMINAL HYPERTENSION AND ABDOMINAL COMPARTMENT SYNDROME IN SEVERE ACUTE PANCREATITIS.

POSTER SESSION II. P092-177**CLINICAL SCIENCE – CHRONIC PANCREATITIS P092-P125**

Chairs: EWA MALECKA-PANAS (Lodz, Poland), TETSUHIKO ITO (Fukuoka, Japan)

P-92

B. Diaconu, L. Ciobanu, T. Mocan, R. Pfueter, M. Scafaru, M. Singer, A. Schneider: INVESTIGATION OF THE SPINK1 N34S MUTATION IN ALCOHOLIC CHRONIC PANCREATITIS IN ROMANIA: A CLINICAL ANALYSIS BASED ON THE CRITERIA OF THE M-ANNHEIM CLASSIFICATION.

P-93

N. Gubergrits, Y. Linevsky: PECULIARITIES OF SYNDROME OF BACTERIAL OVERGROWTH AND ITS TREATMENT IN CHRONIC PANCREATITIS.



P-94

N. Gubergits, Y. Zagoren: PECULIARITIES OF SCLEROSING CHOLANGIOPANCREATITIS IN CASE OF PRIMARY SCLEROSING CHOLANGITIS OR AUTOIMMUNE PANCREATITIS.

P-95

N. Gubergits, N. Byelyayeva: THERAPY OF CHRONIC PANCREATITIS (CP) IN PATIENTS WITH POSTCHOLECYSTECTOMY SYNDROME (PCES).

P-96

L. Heyries, X. Lagrange, J. Bernrad, J. Sahel: EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY IN THE SAME TIME OF ERCP FOR ENDOSCOPIC TREATMENT OF CHRONIC PANCREATITIS.

P-97

D. Fischer, S. Büttner, J. Mössner, A. Hoffmeister: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FUNCTION IN PATIENTS WITH CHRONIC PANCREATITIS.

P-98

A. Tirnaveanu, A. Gal, A. Lenghel: THE INCIDENCE OF CHRONIC PANCREATITIS IN PATIENTS WITH CHRONIC LIVER DISEASE.

P-99

S. T. Barbu, C. Vlad, M. Cazacu:

MORTALITY IN CHRONIC PANCREATITIS: FREQUENCY, CAUSES, AND RISK FACTORS.

P-100

A. F. Barbu, S. T. Barbu: DIABETES MELLITUS IN CHRONIC PANCREATITIS PATIENTS: INCIDENCE AND RISK FACTORS.

P-101

C. Brient, E. Frampas, C. Perret, M. Charvin, E. Dassonneville, N. Regenet: MANAGEMENT OF BLEEDING COMPLICATIONS IN PANCREATITIS.

P-102

N. Byelyayeva: ULTRASOUND DIAGNOSIS OF PANCREAS ADIPOSE DYSTROPHY IN PATIENTS WITH COMBINATION OF CHRONIC PANCREATITIS AND OBESITY.

Chairs: **GYULA FARKAS** (Szeged, Hungary), **ALEXANDER SCHNEIDER** (Mannheim, Germany)

P-103

E. Ileana, B. Diaconu, M. Tantau, R. Laugier: EFFICACY OF ENDOSCOPIC TREATMENT IN CHRONIC PANCREATITIS ASSESSED BY IZBICKI SCORE.

P-104

I. Jovicic, L. Petronijevic, L. Deni, G. Golubovi, M. Konti: EPIDEMIOLOGY OF ACUTE PANCREATITIS IN BELGRADE.

P-105

T. Kendzerska, T. Khrystych: BLOOD LYMPHOCYTE APOPTOTIC ACTIVITY IN AGED PATIENTS WITH CHRONIC PANCREATITIS.

P-106

T. Khrystych, V. Pishak: ENZYMATIC ACTIVITY OF PANCREAS IN PATIENTS WITH CHRONIC PANCREATITIS TAKING INTO ACCOUNT SEASONAL CHRONORHYTHMS.

P-107

M. Tantau, O. Mosteanu, T. A. Pop, A. Tantau, B. Pintea, G. Mester: ENDOSCOPIC PANCREATIC DUCT STENTING FOR CHRONIC PANCREATITIS WITH LONG TERM FOLLOWUP: A ROMANIAN EXPERIENCE.

P-108

M. Tantau, O. Mosteanu, T. A. Pop, A. Tantau, B. Pintea, G. Mester: OVERALL SUCCESS RATES IN THE OUTCOME OF PURE ENDOSCOPIC DRAINAGE OF PSEUDOCYSTS: EXPERIENCE IN ROMANIA.

P-109

G. Orac, J. Pertkiewicz, B. Oralewska, M. Dadalski, J. Kierkus, D. Celinska-Cedro, J. Ryzko, J. Socha: PANCREATIC PSEUDOCYSTS IN CHILDREN WITH CHRONIC PANCREATITIS.

P-110

V. Egorov, V. Vishnevsky, G. Karmazanovsky, A. Schegolev, N. Yashina, L. Vinokurova, H. Dubova: PANCREATIC CANCER OR LOCAL FORM OF AUTOIMMUNE PANCREATITIS: IS IT POSSIBLE TO DIFFERENTIATE THEM PREOPERATIVELY?

P-111

A. Pap, M. Burai, A. Tarpay, S. Otto: TWO-PHASE INDIRECT PANCREATIC FUNCTION TESTS FOR INDIVIDUAL ENZYME REPLACEMENT THERAPY.

P-112

C. Serban, L. Susan, A. Pacurari, C. Banciu, S. Gotia, I. Romosan: LONGITUDINAL STUDY OF ETHIOLOGY OF CHRONIC PANCREATITIS.

P-113

C. Serban, L. Susan, A. Pacurari, C. Banciu, S. Gotia, G. Savoiu, I. Romosan: MODIFICATION OF SERUM LIPID PROFILE IN CHRONIC PANCREATITIS PATIENTS.



Chairs: SERGIO PEDRAZZOLI (Padua, ITA), AKOS PAP (Budapest, Hungary)

P-114

A. Sevcikova, V. Zboril, L. Prokopova, I. Novotny: AZATHIOPRINE AND INDUCTION OF ACUTE PANCREATITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS.

P-115

N. Shirinskaya, et al.: WITHDRAWN

P-116

N. Shirinskaya, et al.: WITHDRAWN

P-117

A. Seicean, T. Mocan, R. Seicean, M. Grigorescu, T. Pop, O. Mosteanu: PREDICTIVE FACTORS OF IMPROVEMENT OF QUALITY OF LIFE AFTER TREATMENT FOR ALCOHOLIC CHRONIC PANCREATITIS.

P-118

L. Susan, C. Serban, V. Ancusa, C. Banciu, S. Gotia, A. Pacurari, N. Mavritsakis, I. Romosan: INCIDENCE OF CHRONIC PANCREATITIS DUE TO CHRONIC ALCOHOL ABUSE.

P-119

J. Teleki. CARBOHYDRATE METABOLISM DISORDERS IN PATIENTS SUFFERING FROM CHRONIC PANCREATITIS WITH ACCOMPANYING CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

P-120

T. Winternitz, M. Borsodi, L. Nehez, B. Tihanyi, T. Tihanyi: ULTRASOUND AND ENDOSCOPIC ULTRASOUND GUIDED CELIAC GANGLION BLOCKADE AT PATIENTS SUFFERING FROM PANCREATIC DISEASES.

P-121

G. Farkas Jr, Y. Mandi, G. Farkas, G. Lazar: THE SUCCESSFUL SURGICAL TREATMENT OF CHRONIC PANCREATITIS IN THE VIEW OF TGF BETA1 AND IL-8 POLYMORPHISM.

P-122

O. Fediv, T. Kendzerska, D. Gontsaryuk: ADAPTIVE PROCESSES IN PATIENTS WITH CHRONIC PANCREATITIS.

P-123

A. Gasiorowska, R. Talar-Wojnarowska, L. Czupryniak, A. Borkowska, J. Loba, E. Malecka-Panas: GLUCOSE TOLERANCE, INSULIN SENSITIVITY, SUBCLINICAL INFLAMMATION AND ENDOTHELIAL DYSFUNCTION IN SUBJECTS WITH CHRONIC PANCREATITIS.

P-124

D. Knezevic, I. Ignjatovic, S. Ostojic, Z. Djordjevic, S. Matic, V. Dugalic, S. Knezevic: DEGREE OF MATURATION OF THE WALL OF PANCREATIC PSEUDOCYST-A CHOICE OF SURGICAL PROCEDURE.

P-125

D. Knezevic, I. Ignjatovic, S. Ostojic, D. Stefanovic, Z. Djordjevic, I. Pavlovic, S. Knezevic: EXTENDED DRAINAGE PROCEDURES VS RESECTION PROCEDURES IN SURGICAL TREATMENT OF CHRONIC PANCREATITIS.

CLINICAL SCIENCE – PANCREATIC CANCER P126-P164

Chairs: EITHNE COSTELLO (Liverpool, UK), RALF SEGERSVARD (Stockholm, Sweden)

P-126

C. Brient, N. Regenet, L. Sulpice, S. M. Hennekinne, A. Ayav, N. Carrere, E. Frampas, B. Meunier, A. Hamy, L. Brunaud, E. Mirallie: EUCLATION FOR PANCREATIC ENDOCRINE TUMORS: A HIGHER RISK OF POSTOPERATIVE FISTULA?

P-127

A. Bursics, T. Gyokeres, A. Pap, J. Vachaja, A. Uhlyarik, Z. Papai, B. Pornczci: IS PANCREATIC CANCER STILL AN UNCURABLE DISEASE?

P-128

Y. T. Chang, C. Hsu, S. C. Wei, G. T. Huang, J. C. Hsu, J. M. Wong, M. C. Chang: CHRONIC HEPATITIS B VIRUS AND HEPATITIS C VIRUS INFECTION ARE NOT ASSOCIATED WITH PANCREATIC CANCER IN TAIWAN - A HIGH ENDEMIC AREA.

P-129

L. Czako, A. Szepes, T. Baranyai, Z. Szepes, T. Molnar, T. Takacs, T. Wittmann: ROLE OF ENDOSCOPIC ULTRASONOGRAPHY IN THE DIAGNOSIS AND PREOPERATIVE STAGING OF PANCREATIC CANCER.

P-130

J. Larino-Noia, J. Iglesias-Garcia, J. E. Dominguez-Munoz: SECOND-GENERATION EUS-ELASTOGRAPHY FOR THE DIFFERENTIAL DIAGNOSIS OF SOLID PANCREATIC MASSES: A QUANTITATIVE ANALYSIS OF TISSUE STIFFNESS.

P-131

V. Dugalic, M. Gojnic Dugalic, D. Knezevic, I. Ignjatovic, M. Petrovic, S. Knezevic: PROGNOSTIC FACTORS AFTER RESECTION OF PANCREATIC HEAD CARCINOMA.

P-132

V. Egorov, V. Vishnevsky, I. Kozlov, T. Shevchenko, O. Melekina: SHORT-TERM RESULTS OF PANCREATODUENECTOMIES EXTENDED AT THE EXPENSE OF LYMPHADENECTOMY, VASCULAR AND EXTENSIVE PANCREATIC BODY RESECTION.



P-133

V. Fendrich, J. Rehm, K. Maschuw, J. Waldmann, E. Slater, D. Bartsch: THE HEDGEHOG INHIBITOR CYCLOPAMINE IS AN EFFECTIVE CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC AGENT IN TRANSGENIC RIP1TAG2 MICE.

P-134

T. Gyokeres, K. Rabai, E. Schafer, K. Ruzsnyak, J. Banai: ERCP IN PATIENTS OVER 80 YEARS – OUR EXPERIENCES.

Chairs: PHILIPPE LEVY (Clichy Cedex, France), RICHARD CHARNLEY (Newcastle, UK)

P-135

I. Ignjatovic, D. Knezevic, I. Pavlovic, S. Knezevic, M. Jagodic, V. Dugalic, S. Matic: COMPARISON OF THE RESULTS AFTER RADICAL SURGICAL PROCEDURES FOR PERIAMPULLARY MALIGNANCIES.

P-136

K. Borka, A. Korompay, E. Szabó, P. Kaliszky, P. Kupcsulik, Z. Schaff, A. Kiss: CLAUDIN EXPRESSION IN DIFFERENTIAL DIAGNOSTICS OF PANCREATIC TUMORS.

P-137

O. Kustro, J. Kryuchina, O. Dronov: MELANOMA OF THE PANCREAS AND GUT: REPORT OF CASES AND REVIEW OF THE LITERATURE.

P-138

Y. Le Baleur, A. Couvelard, M. P. Vullierme, A. Sauvanet, V. Rebours, O. Hentic, F. Maire, P. Hammel, P. Ruszniewski, P. Lévy: CT SCAN ALLOWS ACCURATE PREOPERATIVE DIAGNOSIS OF MALIGNANCY IN PATIENTS WITH PANCREATIC MUCINOUS CYSTADENOMAS.

P-139

A. Aubert, P. Lévy, P. Ponsot, A. Couvelard, F. Maire, V. Rebours, O. Hentic, M. Felce-Dachez, L. Palazzo, M. Vullierme, P. Hammel, P. Ruszniewski: IS DIAGNOSTIC YIELD OF ENDOSCOPIC ULTRASOUND GUIDED FINE-NEEDLE ASPIRATION/BIOPSY (EUSFNAB) AFFECTED BY PREVIOUS BILIARY STENTING ?

P-140

A. López, S. Chacón, I. Ortega, J. L. Rodrigo, H. Hallal, J. Tudela, E. Pérez-C: NON FUNCTIONING, METASTATIC CYSTIC PANCREATIC ENDOCRINE TUMOR. MOST PROMINENT FEATURES OF THIS TYPE OF NEOPLASMS.

P-141

P. Meszaros, N. Szucs, M. Bely, B. Megadja, A. Bursics: LAPAROSCOPICALLY REMOVED RETROPERITONEAL EXTRAADRENAL PHEOCROMOCYTOMA PRESENTING AS A PANCREATIC MASS - VIDEO PRESENTATION.

P-142

D. Munteanu, C. Iancu, D. Todea-Iancu, C. Ghenea, B. Tunas, T. Mocan, L. Mocan, A. Munteanu, S. Gergeanu, F. Zaharie, L. Vlad: PANCREATICODUODENECTOMY FOR PERIAMPULLARY TUMORS.

P-143

D. Munteanu, C. Iancu, D. Todea-Iancu, C. Ghenea, B. Tunas, T. Mocan, L. Mocan, A. Munteanu, S. Gergeanu, F. Zaharie, L. Vlad: PANCREATICODUODENECTOMY FOR PERIAMPULLARY TUMORS. EXPERIENCE MATTERS.

P-144

L. Nehez, B. Tihanyi, T. Winternitz, T. Tihanyi: MINIMAL INVASIVE APPROACH IN SOLITAER PANCREATIC LAESIONS.

Chairs: PHILIPPE RUSZNIEWSKI (Clichy Cedex, France), ATTILA OLAH (Gyor, Hungary)

P-145

C. Macutkiewicz, M. Manu, D. Sherlock, D. O'Reilly: PLATELET-LYMPHOCYTE RATIO AND SERUM CARBOHYDRATE ANTIGEN 19-9 LEVELS AID IN PATIENT SELECTION FOR STAGING LAPAROSCOPY IN SUSPECTED PANCREATIC MALIGNANCY.

P-146

M. Ouaiissi, J. Tavares, I. Sieleznieff, B. Sastre, J. Bernard, E. Mas, D. Lombardo, A. Cordeiro Da Silva, A. Ouaiissi, P. Kong Ling: BISNAPHTHALIMIDOPROPYL DERIVATIVES AS NEW DRUG INHIBITORS OF PANCREATIC CANCER CELLS GROWTH.

P-147

M. Ouaiissi, R. Verhelst, P. Astarci, G. Ei Khouri, C. Hubert, B. Van Beers, L. Annet, P. Goffette, P. Noirhomme, J. F. Gigot: CELIAC ARTERY OCCLUSIVE DISEASE: A RARE BUT POTENTIALLY CRITICAL CONDITION IN PATIENTS UNDERGOING PANCREATICO-DUODENECTOMY.

P-148

A. Tarpay, E. Szaleczky, E. Toth, A. Pap: NON-HODGKIN –MALT LYMPHOMA OF LUNG WITH SYSTEMIC DISSEMINATION IN THE STOMACH AND GALLBLADDER ACCOMPANIED BY ADENOCARCINOMA OF THE URINARY BLADDER AND THE PANCREAS.

P-149

C. Sperti, M. Berselli, S. Pedrazzoli: DISTAL PANCREATECTOMY FOR BODY-TAIL PANCREATIC CANCER. IS THERE A ROLE FOR CELIACAXIS RESECTION?

P-150

F. Pinter, E. Szabo, M. Kanya, J. Papay, Z. Sapi, L. Berczi, A. Tamasi, A. Kovesdi, E. Varkondi, T. Micsik, L. Kopper, R. Schwab, I. Petak: SIGNIFICANCE OF PRECISE IDENTIFICATION OF DIFFERENT KRAS GENE MUTATIONS BY SEQUENCING BASED MOLECULAR DIAGNOSTIC METHOD IN GASTROINTESTINAL ADENOCARCINOMAS.

P-151

D. A. Raptis, C. Fessas, P. Belasyse-Smith, J. Skipworth, R. Graf, T. R. Kurzawinski: **CLINICAL PRESENTATION AND WAITING TIME TARGETS DO NOT AFFECT PROGNOSIS IN PATIENTS WITH PANCREATIC CANCER.**

P-152

M. Ryska, F. Belina, R. Strnad, M. Zavoral, E. Laszikova, I. Buric, P. Hrabal: **LONG-TERM SURVIVAL AFTER SURGERY FOR HEAD PANCREATIC CARCINOMA.**

P-153

L. Sabater, L. Aparisi, J. Calvete, R. Canovas, E. Muñoz, R. Añon, S. Rosello, E. Rodriguez, B. Camps, R. Alfonso, C. Sala, J. Sastre, A. Cervantes, S. Lledo: **PANCREATIC AND PERIAMPULLARY TUMORS: SURGICAL AND FUNCTIONAL RESULTS IN A SPANISH INSTITUTION. A CONSECUTIVE SERIES OF 160 CASES.**

P-154

P. Simon, E. Dickson, M. Lerch, R. Carter, C. McKay: **ENDOSCOPIC ULTRASOUND GUIDED ELASTOGRAPHY COMPARED TO EUS AND EUS GUIDED FNA IN SOLID MASS LESIONS OF THE PANCREAS. A PROSPECTIVE STUDY IN 30 PATIENTS.**

Chairs: NATALYA GUBERGRITS (Donetsk, Ukraine), **SORIN BARBU** (Cluj-Napoca, Romania)

P-155

C. Sperti, M. Moro, F. Tona, L. Frison, S. A. Canton, C. Pasquali, S. Pedrazzoli: **PROGNOSTIC RELEVANCE OF LYMPH NODE STATUS AFTER RESECTION FOR PANCREATIC CANCER.**

P-156

A. Seicean, R. Badea, R. Stan-luga, T. Pop: **THE VALUE OF REAL-TIME HARMONICS CONTRAST-ENHANCED ENDOSCOPIC ULTRASONOGRAPHY (SONOVUE) WHEN CHARACTERIZING THE PANCREATIC TUMORS.**

P-157

R. Talar-Wojnarowska, A. Gasiorowska, M. Olakowski, A. Lekstan, P. Lampe, B. Smolarz, H. Romanowicz-Makowska, A. Kulig, E. Malecka-Panas: **CLINICAL VALUE OF SERUM NEOPTERIN, TPS AND CA19-9 LEVELS IN PATIENTS WITH PANCREATIC ADENOCARCINOMA AND CHRONIC PANCREATITIS.**

P-158

B. Tihanyi, B. Jori, Z. Nemoda, T. Micsik, T. Krenacs, A. Lorincz, T. Tihanyi, P. Kupcsulik, L. Nehez, M. Sasvari-Szekely, T. Szuts, L. Orfi, G. Keri, L. Kopper, R. Schwab, I. Petak: **QPCR-BASED MOLECULAR DIAGNOSTICS OF LOCAL M2PK EXPRESSION IN PANCREATIC CANCER CAN PLAY AN IMPORTANT ROLE IN THE PREDICTIVE DIAGNOSTICS OF NOVEL M2PK-TARGETED DRUGS.**

P-159

T. Dumitrascu, L. David, I. Popescu: **DOES POSTERIOR APPROACH INFLUENCE POSTOPERATIVE OUTCOME AND SURVIVAL IN PANCREATIC CANCER? RESULTS FROM A CASEMATCH STUDY WITH STANDARD PANCREATODUODENECTOMY.**

P-160

L. Hodkin, A. Anthoney, D. Treanor, R. Albazaz, C. Verbeke: **HETEROGENEITY OF PROLIFERATIVE ACTIVITY IN PRIMARY AND METASTATIC PANCREATIC ENDOCRINE CARCINOMAS.**

P-161

J. Werner, T. Hackert, U. Hinz, M. Hassenpflug, O. Strobel, M. W. Büchler: **MULTIVISCERAL RESECTION FOR PANCREATIC MALIGNANCIES: RISKANALYSIS AND LONG-TERM OUTCOME.**

P-162

O. Strobel, T. Hackert, W. Hartwig, F. Bergmann, M. Wente, U. Hinz, S. Fritz, L. Schneider, M. W. Büchler, J. Werner: **SURGERY FOR PANCREATIC MATASTASES: CLINICAL AND LONG-TERM OUTCOME WITH ANALYSIS OF PROGNOSTIC FACTORS.**

P-163

T. Hackert, W. Hartwig, U. Hinz, L. Schneider, O. Strobel, M. W. Büchler, J. Werner: **SURGICAL AMPULLECTOMY – INDICATIONS, TECHNIQUE AND OUTCOME IN 51 CONSECUTIVE PATIENTS.**

P-164

N. Zanini, M. Masetti, L. Mastrangelo, F. Martuzzi, M. F. Lerro, E. Jovine: **SURVIVAL AND PROGNOSTIC FACTOR ANALYSIS IN PATIENTS WITH PANCREATIC METASTASIS.**

CLINICAL SCIENCE – Miscellaneous P165-P176

Chairs: ZOLTAN BERGER (Santiago, Chile), **TAMAS TAKACS** (Szeged, Hungary)

P-165

A. Gherbon, L. Noveanu, G. Mihalas: **POLYGLANDULAR AUTOIMMUNE SYNDROME IN ADULTS WITH DIABETES MELLITUS.**

P-166

A. Gherbon, L. Noveanu, G. Mihalas: **PREVALENCE OF METABOLIC SYNDROME AND ITS IDENTIFICATION CRITERIA BY SEX AT PATIENTS WITH DIABETES MELLITUS TYPE 1 AND CHRONIC AUTOIMMUNE THYROIDITIS.**

P-167

L. S. Gotia, S. R. Gotia, C. Gurban: **DIABETES MELLITUS ASSOCIATED WITH ORAL TUMORS.**

P-168

A. Kazuyulin, I. Koroleva, Y. Kucheryavy, M. Byahov: **PANCREATIC TOXICITY DURING AND AFTER TAXANANTHRACYCLINE- BASED NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER.**

P-169

A. Kozachenko: **COMPARATIVE EPIDEMIOLOGY AND RISK FACTORS ANALYSIS OF THE ACUTE PANCREATITIS AND LESIONS OF SALIVARY GLANDS.**

P-170

P. G. Lankisch, J. Griesche-Philippi, J. Otto, P. Maisonneuve: **EXOCRINE PANCREATIC INSUFFICIENCY IN ENDSTAGE RENAL DISEASE.**

P-171

S. Matic, R. Colovic, M. Milicevic, M. Jovanovic, S. Knezevic, D. Knezevic, N. Grubor, S. Latinic: **CYSTADENOMAS OF THE PANCREAS.**

P-172

S. Milic, B. Kezele, D. Jurisic Erzen, G. Poropat, V. Vlahovic Palcevski, D. Stimac: **SCREENING FOR PANCREATIC EXOCRINE INSUFFICIENCY IN PATIENTS WITH ALCOHOLIC CIRRHOSIS, DIABETIC PATIENTS AND THOSE RECOVERED FROM PREVIOUS ACUTE PANCREATITIS.**

P-173

D. A. Raptis, R. Vonlanthen, S. Breitenstein, K. Slankamenac, P. A. Clavien, R. Graf: **A PROSPECTIVE COST ANALYSIS OF PANCREATIC SURGERY AND ITS COMPLICATIONS.**

P-174

R. Badea, A. Seicean, B. Diaconu, M. Socaciu, R. Stan-luga, Z. Sparchez, M. Tantau, A. Serban: **THE VALUE OF REAL TIME CONTRAST-ENHANCED ULTRASONOGRAPHY (SONOVUE) WHEN CHARACTERIZING THE MICROCIRCULATION IN PANCREATIC DISEASE.**

P-175

A. Seicean, R. Stan-luga, T. Mocan, C. Iancu: **FAILURE TO DRAIN PANCREATIC PSEUDOCYSTS BY EUS WITHOUT FLUOROSCOPY.**

P-176

Y. Zagorenko: **PANCREAS EXCRETORY FUNCTION IN NON-SPECIFIC ULCERATIVE COLITIS.**



A series of horizontal dotted lines for taking notes, spanning the width of the page.



HIRSHBERG FOUNDATION FOR PANCREATIC CANCER RESEARCH

ABOUT THE FOUNDATION

Founded in 1997, the Hirshberg Foundation for Pancreatic Cancer Research is a national, non-profit organization dedicated to advancing pancreatic cancer research, and providing information, resources and support to pancreatic cancer patients and their families

Since our inception, the Hirshberg Foundation has:

- Raised more than \$8.5 million for pancreatic cancer research
- Granted over \$500,000 in financial aid for patients
- Provided assistance to thousands of patients and their families
- Expanded seed grant funding to Loma Linda University, City of Hope, John Hopkins Medical Center, Mayo Clinic, Columbia University, and University of Minnesota. Our Seed Grant Award Recipients have received 14 million dollars in NIH grants
- Presented the Agi Hirshberg Symposium at UCLA, focusing on research progress and patient help
- Funding the creation of the Tissue Data Bank at UCLA
- Awarded international grants to new investigators

For more information about the Hirshberg Foundation,
please visit our website at www.pancreatic.org

*Seed Grant Application Deadline is August 15th, 2009



Ettől bizonyosan
eláll a sava!



RICHTER GEDEON



1103 Budapest, Gyömrői út 19-21. Operatív Marketing Osztály: 432 6148 www.richter.hu Gyógyszerbiztonsági osztály: 505 7032 drugsafety@richter.hu

Hatóanyag: 30 mg lansoprazolum kapszulánként **Terápiás javallatok:** Gastro-oesophagealis refluxbetegség gyógyítása és hosszú távú kezelése. Ulcus duodeni, benignus ulcus ventriculi, reflux oesophagitis, a H₂-receptor antagonistákra nem reagáló esetekre is. Helicobacter pylori eradikációja a felső gastrointestinalis tractusból, megfelelő antibiotikum kombinációban. Savas dyspepsiával összefüggő tünetek (gyomorégés, felső epigastriális fájdalom) enyhítése. NSAID-kezeléssel kapcsolatos benignus gyomorfekély és nyombélfekély kezelése, ill. profilaxisa; a tartós NSAID-kezelés mellékhatásainak csökkentése. Fokozott savtermeléssel járó kóros állapotok (beleértve a Zollinger-Ellison szindrómát) hosszú távú kezelése. **Ellenjavallatok:** A készítmény bármely összetevője iránti túlérzékenység. Terhesség, Szoptatás. Gyermekkor (elegendő klinikai tapasztalatok hiányában). Rosszindulatú gyomorfekély, malignus oesophagus-megbetegedés. **Mellékhatások:** A Lansone kapszula szedése során jelentkező mellékhatások általában enyhék és átmenetiek. Leggyakrabban észlelt nemkívánatos hatások: fejfájás, tremor, álmatlanság, diarhoea, hasi fájdalom, dyspepsia, szájszárazság, obstipatio, flatulencia, nausea, emesis, candidiasis, vertigo, fáradtságérzés, bőrkiütés, urticaria, pruritus, a májfunkciós vizsgálatok értékeinek átmeneti emelkedése. **Ár és rendelkezés:** 7x normatív támogatás: 415 Ft, térítési díj: 487 Ft, 14x normatív támogatás: 829 Ft, térítési díj: 980 Ft, 28x normatív támogatás: 1658 Ft, térítési díj: 1 963 Ft **Forgalombahozatali engedély száma:** OGYI-T-5156/01-03 **További részletes információkat az alkalmazási előírat tartalmaz.**

Quamatel[®]

(famotidin)

Célbalőni..., a kérdés, hogy

MIRE és MIVEL?




RICHTER GEDEON

1103 Budapest, Gyömri út 19-21. Operatív Marketing Osztály: 432 6148 www.richter.hu
Gyógyszerbiztonsági Osztály: 505 7032 drugsafety@richter.hu

Quamatel 20mg, ill. 40mg filtabletta Hatóanyag: 20mg, ill. 40mg famotidinum tablettánként. **Terápiás javallatok:** Nyombél- és jóindulatú gyomorreflex, gastro-oesophagealis reflux és egyéb gyomorsav túlermeléssel járó megbetegedések (pl. Zollinger- Ellison szindróma) kezelése, fekélyrecidíva megelőzése, általános anaesthesia esetén a savaspiráció (Mendelson szindróma) megelőzése. **Ellenjavallatok:** A készítmény bármely összetevője iránti túlérzékenység. Terhesség. Szoptatás. Gyermekkor (elegendő klinikai tapasztalatok hiányában). **Mellékhatások:** Ritkán fejfájás, szédülés, hasmenés vagy székrekedés. **Rendelhetőség:** Csak vényre kiadható gyógyszer. **Teljes ár / TB támogatás / Beteg fizet:** 20 mg 28x 739 / 340 / 399 Ft; 20 mg 60x 1547 / 729 / 818 Ft; 40 mg 14x 609 / 281 / 328 Ft; 40 mg 30x 1296 / 603 / 693 Ft. Az új közlőny megjelenésével az árak változhatnak. **Forgalombahozatali engedély száma:** OGYI-T-3848/01-02, OGYI-T-3849/01-02 **További részletes információkat az alkalmazási előírat tartalmaz.** Az esetleges változások a www.oep.hu honlapon tekinthetők meg.

Folyamatos Innováció



Kreon[®]

Kreon[®]10000

Kreon[®]25000

Alkalmazási előírat: Kreon[®] 10000 kapszula (20x 50x): 150 mg pancreatinum kapszulánként (10000 Ph. Eur. E. lipáz, 8000 Ph. Eur. E. amiláz és 600 Ph. Eur. E. proteáz), Kreon[®] 25000 kapszula (50x 100x): 300 mg pancreatinum kapszulánként (25000 Ph. Eur. E. lipáz, 18000 Ph. Eur. E. amiláz és 1000 Ph. Eur. E. proteáz). Terápiás javallatok: Exokrin pancreaselégtelenség kezelése gyermekeknél és felnőtteknél. Az exokrin pancreaselégtelenség gyakran együtt jár az alábbi körképekkel (bár nem korlátozódik kizárólag ezekre az esetekre): • mucoviscidosis, • krónikus pancreatitis, • pancreatocytoma utáni állapot, • gastrectomia, • hasnyálmirigy-ér, • gastrointestinalis bypass műtét utáni állapot (Pl. Billroth II gastroenterostomia), • a ductus pancreaticus vagy a ductus choledochus elzáródása (pl. daganat következtében), • Shwachman-Diamond-szindróma. Adagolás és alkalmazás: A kapszulákat egységben, szétitrés vagy szétrágás nélkül, étkezés közben, elegendő mennyiségű folyadékkal kell lenyelni. Adagolás mucoviscidosisban: • A testúlyfüggő enzimadagolást testtömegkilogrammonként és étkezésenként 1000 egységnyi lipázzal kell kezdeni 4 éven aluli gyermekeknél, ill. 500 egységnyi lipázzal 4 éven felülieknél. • Az adagot a betegség súlyossági fokának megfelelően kell megállapítani oly módon, hogy az biztosítsa a steatorrhoea visszaszorítását, valamint a beteg megfelelő tápláltsági állapotát. • A betegek többségénél a napi adag maradjon 10 000 lipázegység/tkg alatt, ill. ne haladja meg azt. Adagolás az exokrin pancreaselégtelenség egyéb esetelben: A szükséges adag 20–75000 Ph. Eur. egység lipáz a főétkezésekhez (reggeli, ebéd, vacsora) és kb. 5–25000 Ph. Eur. egység lipáz a köztes étkezésekhez. A szokásos kezdő adag 10–25000 Ph. Eur. egység lipáz főétkezésenként. A steatorrhoea minimalizálásához és megfelelő tápláltsági állapot biztosításához azonban ennél nagyobb adagok alkalmazására is szükség lehet. Az általános klinikai gyakorlat azt mutatja, hogy étkezésenként legalább 20–50000 Ph. Eur. egység lipáz kell bejutni. Ellenjavallatok: Túlérzékenység a sertéspancreasból nyert pankre atinnal, illetve a készítmény bármely összetevőjével szemben. Nemkívánatos hatások, mellékhatások: Klinikai vizsgálatok összesített adatai szerint a pankreatin alkalmazásával kapcsolatos gyógyszer mellékhatások összincidenciája azonos volt a placebóval tapasztaltakkal. Gastrointestinalis zavarok: Hasi fájdalom (gyakori), székrekedés (ritka), abnormális széklet (ritka), diarrhoea (ritka) és hányás/hányinger (ritka). Elővigyázatosságból azonban szokatlan hasi tünetek jelentkezése, ill. a hasi tünetek megváltozása esetén megfelelő vizsgálattal ki kell zárni a colónkárosodás lehetőségét, különösen akkor, ha a beteg napi lipázbevétele meghaladja a testsúlykilogrammonkénti 10 000 egységet. A bőr, ill. a bőr alatti kötőszövet elváltozásai. Előfordultak allergiás vagy túlérzékenységi bőrreakciók is (ritka). Megjegyzés: (egy keresztl) jelzés. Kiadhatóság: Kreon 10 000 vény nélküli kiadható gyógyszer (I. csoport), OGYI-T-05809, 04231 Szöveg ellenőrzésének dátuma: 2008. 07. 16. Az aktuális ár megtekinthető a www.oep.hu honlapon. Ár: Kreon 10 000 (20x) fagy. ár: 779 Ft., 0% tám., tér. díj: 779 Ft., EU 70% tám., 545 Ft., EU 70 tér. díj: 234 Ft., EU 100% tám., 479 Ft., EU 100 tér. díj: 300 Ft.; Kreon 10 000 (50x) fagy. ár: 1 503 Ft., 0% tám., tér. díj: 1 503 Ft., EU 70% tám., 1 052 Ft., EU 70 tér. díj: 451 Ft., EU 100% tám., 1 203 Ft., EU 100 tér. díj: 300 Ft.; Kreon 25 000 (50x) fagy. ár: 4 646 Ft., 0% tám., tér. díj: 4 646 Ft., EU 70% tám., 2 766 Ft., EU 70 tér. díj: 1 880 Ft., EU 100% tám., 4 346 Ft., EU 100 tér. díj: 300 Ft.; Kreon 25 000 (100x) fagy. ár: 8 457 Ft., 0% tám., tér. díj: 8 457 Ft., EU 70% tám., 5 533 Ft., EU 70 tér. díj: 2 924 Ft., EU 100% tám., 8 157 Ft., EU 100 tér. díj: 300 Ft.; Forrás: www.oep.hu 2009.03.01. Bővebb információ: Solvay Pharma Kft.

2009/Kreon/Hirdetés/01

SOLVAY PHARMA KFT.
1013 Budapest, Pauler u. 11.
Telefon: 309-5500, Fax: 309-5501
E-mail: info.pharmahungary@solvay.com
www.solvaypharma.hu



SOLVAY
PHARMA Kft.

a Passion for Progress[®]



Reliably Mapping the Pathways to Drug Discovery

**What you eat
is your choice**

Creon[®]

**The right enzyme
replacement therapy
is key**

Creon[®] 40000

Creon[®] 25000

Creon[®] 10000

Creon[®] micro



a Passion for Progress[®]

**Solvay
Pharmaceuticals**

For more information,
please contact your
local Solvay office or visit
www.solvaypharmaceuticals.com

With our strong reputation
for providing highly insightful
metabolic profiling and
analysis, let SiDMAP be your
metabolomics solution partner

Tracer-based, Metabolic Profiling Services to:

- » Determine Drug Effect/Mechanism of Action
- » Identify Clinical Biomarkers for Drug Efficacy or Toxicity
- » Validate Drug Targets

**For more information about SiDMAP
please visit our website at www.sidmap.com**

THE METABOLOMICS SERVICE COMPANY



**What you eat
is your choice**


Creon[®]

**The right enzyme
replacement therapy
is key**


Creon[®] 40000


Creon[®] 25000


Creon[®] 10000


Creon[®] micro

For more information,
please contact your
local Solvay office or visit
www.solvaypharmaceuticals.com

**Solvay
Pharmaceuticals**



a Passion for Progress[®]